ATE356824T1 - L-ribo-lna analoge - Google Patents

L-ribo-lna analoge

Info

Publication number: ATE356824T1
Authority: AT; Austria
Prior art keywords: ribo; compounds; lna analogue; lna; analogue
Prior art date: 1999-05-04

Application number

AT00925080T

Other languages

English (en)

Inventor

Jesper Wengel

Original Assignee

Santaris Pharma As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-05-04

Filing date

2000-05-04

Publication date

2007-04-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27220811&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE356824(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-05-04 Application filed by Santaris Pharma As filed Critical Santaris Pharma As

2007-04-15 Application granted granted Critical

2007-04-15 Publication of ATE356824T1 publication Critical patent/ATE356824T1/de

Links

108091034117 Oligonucleotide Proteins 0.000 abstract 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
125000002619 bicyclic group Chemical group 0.000 abstract 1
230000000295 complement effect Effects 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
108020004707 nucleic acids Proteins 0.000 abstract 1
150000007523 nucleic acids Chemical class 0.000 abstract 1
102000039446 nucleic acids Human genes 0.000 abstract 1
239000002777 nucleoside Substances 0.000 abstract 1
-1 nucleoside compounds Chemical class 0.000 abstract 1
238000003786 synthesis reaction Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
- C07H9/02—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing only oxygen as ring hetero atoms
- C07H9/04—Cyclic acetals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Oncology (AREA)
Saccharide Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Investigating Or Analysing Biological Materials (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT00925080T 1999-05-04 2000-05-04 L-ribo-lna analoge ATE356824T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DKPA199900603		1999-05-04
DKPA199901225		1999-09-01
DKPA200000032		2000-01-11

Publications (1)

Publication Number	Publication Date
ATE356824T1 true ATE356824T1 (de)	2007-04-15

Family

ID=27220811

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT00925080T ATE356824T1 (de)	1999-05-04	2000-05-04	L-ribo-lna analoge

Country Status (16)

Country	Link
US (1)	US7053207B2 (de)
EP (1)	EP1178999B1 (de)
JP (1)	JP2002543214A (de)
KR (1)	KR100782896B1 (de)
CN (2)	CN1349541A (de)
AT (1)	ATE356824T1 (de)
AU (1)	AU776362B2 (de)
CA (1)	CA2372085C (de)
DE (1)	DE60033927T2 (de)
DK (1)	DK1178999T3 (de)
ES (1)	ES2283298T3 (de)
HK (1)	HK1048322A1 (de)
IL (1)	IL145497A0 (de)
NZ (1)	NZ514348A (de)
PT (1)	PT1178999E (de)
WO (1)	WO2000066604A2 (de)

Families Citing this family (985)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7119184B2 (en) *	1991-08-12	2006-10-10	Isis Pharmaceuticals, Inc.	Oligonucleotides having A-DNA form and B-DNA form conformational geometry
US6794499B2 (en)	1997-09-12	2004-09-21	Exiqon A/S	Oligonucleotide analogues
US7572582B2 (en)	1997-09-12	2009-08-11	Exiqon A/S	Oligonucleotide analogues
PT1152009E (pt)	1999-02-12	2005-03-31	Sankyo Co	Novos analogos de nucleosidos e oligonucleotidos
US6734291B2 (en)	1999-03-24	2004-05-11	Exiqon A/S	Synthesis of [2.2.1]bicyclo nucleosides
DK1163250T3 (da) *	1999-03-24	2006-11-13	Exiqon As	Forbedret syntese af [2.2.1]bicyclonukleosider
AU3041701A (en) *	1999-12-23	2001-07-09	Exiqon A/S	Therapeutic uses of lna-modified oligonucleotides
US8202979B2 (en)	2002-02-20	2012-06-19	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
NZ521698A (en)	2000-03-27	2004-08-27	Univ Delaware	Targeted chromosomal genomic alterations with modified single stranded oligonucleotides
US6936467B2 (en)	2000-03-27	2005-08-30	University Of Delaware	Targeted chromosomal genomic alterations with modified single stranded oligonucleotides
AU2002303176A1 (en)	2001-03-27	2002-10-15	University Of Delaware	Genomics applications for modified oligonucleotides
US9994853B2 (en)	2001-05-18	2018-06-12	Sirna Therapeutics, Inc.	Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US7517864B2 (en)	2001-05-18	2009-04-14	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050148530A1 (en)	2002-02-20	2005-07-07	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
GB0114719D0 (en) *	2001-06-15	2001-08-08	Glaxo Group Ltd	Compound
US9261460B2 (en)	2002-03-12	2016-02-16	Enzo Life Sciences, Inc.	Real-time nucleic acid detection processes and compositions
WO2003020739A2 (en)	2001-09-04	2003-03-13	Exiqon A/S	Novel lna compositions and uses thereof
US7468244B2 (en)	2001-09-27	2008-12-23	University Of Delaware	Polymorphism detection and separation
US7112405B2 (en)	2001-09-27	2006-09-26	University Of Delaware	Compositions and methods for enhancing oligonucleotide-mediated gene alteration
AU2002351077A1 (en) *	2001-11-05	2003-05-19	Exiqon A/S	Oligonucleotides modified with novel alpha-l-rna analogues
CA2471218A1 (en) *	2001-12-21	2003-07-24	Applera Corporation	Heteroconfigurational polynucleotide and methods of use
US20060009409A1 (en)	2002-02-01	2006-01-12	Woolf Tod M	Double-stranded oligonucleotides
WO2003064621A2 (en)	2002-02-01	2003-08-07	Ambion, Inc.	HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
EP3415625A1 (de)	2002-02-01	2018-12-19	Life Technologies Corporation	Doppelsträngige oligonukleotide
AU2003207708A1 (en)	2002-02-20	2003-09-09	Sirna Therapeutics, Inc.	Rna interference mediated inhibition of map kinase genes
US9181551B2 (en)	2002-02-20	2015-11-10	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9657294B2 (en)	2002-02-20	2017-05-23	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
AU2003220119A1 (en)	2002-03-07	2003-09-22	University Of Delaware	Methods, compositions, and kits for enhancing oligonucleotide-mediated nucleic acid sequence alteration using compositions comprising a histone deacetylase inhibitor, lambda phage beta protein, or hydroxyurea
US9353405B2 (en)	2002-03-12	2016-05-31	Enzo Life Sciences, Inc.	Optimized real time nucleic acid detection processes
JP2005521410A (ja) *	2002-03-29	2005-07-21	ジェネンテック・インコーポレーテッド	核酸分析試料の検出と定量化のための方法及び組成物
SI2264172T1 (sl)	2002-04-05	2017-12-29	Roche Innovation Center Copenhagen A/S	Oligomerne spojine za modulacijo izražanja HIF-1alfa
US7569575B2 (en)	2002-05-08	2009-08-04	Santaris Pharma A/S	Synthesis of locked nucleic acid derivatives
JP4476802B2 (ja) *	2002-05-08	2010-06-09	サンタリスファーマアー／エス	ロックト核酸誘導体の製造
AU2003276666A1 (en) *	2002-06-12	2003-12-31	Ambion, Inc.	Methods and compositions relating to polypeptides with rnase iii domains that mediate rna interference
US20100075423A1 (en) *	2002-06-12	2010-03-25	Life Technologies Corporation	Methods and compositions relating to polypeptides with rnase iii domains that mediate rna interference
US20040248094A1 (en) *	2002-06-12	2004-12-09	Ford Lance P.	Methods and compositions relating to labeled RNA molecules that reduce gene expression
US7005265B1 (en)	2002-06-20	2006-02-28	Wenhong Fan	Nonenzymatic catalytic signal amplification for nucleic acid hybridization assays
US20040219565A1 (en)	2002-10-21	2004-11-04	Sakari Kauppinen	Oligonucleotides useful for detecting and analyzing nucleic acids of interest
US9045518B2 (en) *	2002-11-18	2015-06-02	Santaris Pharma A/S	Amino-LNA, thio-LNA and alpha-L-oxy-LN
AU2013201763B2 (en) *	2002-11-18	2015-05-07	Roche Innovation Center Copenhagen A/S	Amino-LNA, thio-LNA and alpha-L-oxy-LN
EP1426448A1 (de) *	2002-12-03	2004-06-09	bioMérieux BV	Methode zur Reduktion des Effektes von Sequenzvariationen in einem diagnostischen Hybridisierungsverfahren, Sonde zur Verwendung in einem solchen Verfahren, sowie das Verfahren selbst
US20060292438A1 (en) *	2002-12-23	2006-12-28	Applera Corporation; Applied Biosystems Group	Heteroconfigurational Polynucleotides and Methods of Use
CA2515623A1 (en)	2003-02-10	2004-08-19	Santaris Pharma A/S	Oligomeric compounds for the modulation of survivin expression
US7713738B2 (en)	2003-02-10	2010-05-11	Enzon Pharmaceuticals, Inc.	Oligomeric compounds for the modulation of survivin expression
US8653252B2 (en)	2003-03-21	2014-02-18	Santaris Pharma A/S	Short interfering RNA (siRNA) analogues
WO2004106356A1 (en) *	2003-05-27	2004-12-09	Syddansk Universitet	Functionalized nucleotide derivatives
ATE553216T1 (de) *	2003-06-20	2012-04-15	Exiqon As	Sonden, bibliotheken und kits zur analyse von nukleinsäuregemischen und verfahren zu deren konstruktion
EP2530157B1 (de)	2003-07-31	2016-09-28	Regulus Therapeutics Inc.	Oligomerverbindungen und Zusammensetzungen zur Verwendung bei der Modulation von miRNAs
US20050053981A1 (en) *	2003-09-09	2005-03-10	Swayze Eric E.	Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
US7480382B2 (en) *	2003-09-30	2009-01-20	Microsoft Corporation	Image file container
ATE404697T1 (de) *	2003-11-07	2008-08-15	Daiichi Sankyo Co Ltd	Verfahren zum nachweis von genetischem polymorphismus
JP4642775B2 (ja)	2003-12-23	2011-03-02	サンタリスファーマアー／エス	Ｂｃｌ−２のモデュレーションのためのオリゴマー化合物
GB0406864D0 (en)	2004-03-26	2004-04-28	Qiagen As	Nucleic acid sequencing
US8192937B2 (en)	2004-04-07	2012-06-05	Exiqon A/S	Methods for quantification of microRNAs and small interfering RNAs
WO2005105157A2 (en)	2004-04-23	2005-11-10	The Trustees Of Columbia University In The City Ofnew York	INHIBITION OF HAIRLESS PROTEIN mRNA
US10508277B2 (en)	2004-05-24	2019-12-17	Sirna Therapeutics, Inc.	Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
EP2290073A3 (de)	2004-05-28	2011-08-31	Asuragen, Inc.	Verfahren und Zusammensetzungen mit MicroRNA
CN101065485B (zh) *	2004-11-09	2011-12-07	桑塔里斯制药公司	Lna寡核苷酸和癌症治疗
US9447138B2 (en)	2004-11-09	2016-09-20	Roche Innovation Center Copenhagen A/S	Potent LNA oligonucleotides for the inhibition of HIF-1a expression
MX2007005558A (es)	2004-11-09	2008-01-31	Santaris Pharma As	Oligonucleotidos de lna potentes para la inhibicion dela expresion de hif-1a.
CA2586701C (en)	2004-11-09	2014-06-03	Santaris Pharma A/S	Lna oligonucleotides and the treatment of cancer
CA2857878A1 (en)	2004-11-12	2006-12-28	Asuragen, Inc.	Methods and compositions involving mirna and mirna inhibitor molecules
US20060166238A1 (en) *	2004-12-22	2006-07-27	Ramsing Niels B	Probes, libraries and kits for analysis of mixtures of nucleic acids and methods for constructing the same
US20060142228A1 (en) *	2004-12-23	2006-06-29	Ambion, Inc.	Methods and compositions concerning siRNA's as mediators of RNA interference
US20070099196A1 (en)	2004-12-29	2007-05-03	Sakari Kauppinen	Novel oligonucleotide compositions and probe sequences useful for detection and analysis of micrornas and their target mRNAs
AU2006213686A1 (en)	2005-02-09	2006-08-17	Avi Bio Pharma, Inc.	Antisense composition and method for treating muscle atrophy
ATE541928T1 (de)	2005-03-31	2012-02-15	Calando Pharmaceuticals Inc	Inhibitoren der untereinheit 2 der ribonukleotidreduktase und ihre verwendungen
US7838502B2 (en)	2005-05-06	2010-11-23	University Of Massachusetts Medical School	Compositions and methods to modulate H. influenzae pathogenesis
ES2397113T3 (es) *	2005-06-23	2013-03-04	Isis Pharmaceuticals, Inc.	Composiciones y procedimientos para modular el corte y empalme de SMN2
US20100015604A1 (en)	2005-08-17	2010-01-21	Evriklia Lianidou	Composition and method for determination of ck19 expression
US20070054872A1 (en) *	2005-08-24	2007-03-08	Mirus Bio Corporation	Regulatable or conditional expression systems
DK1931780T3 (en)	2005-08-29	2016-01-25	Regulus Therapeutics Inc	Antisense-forbindelser med forøget anti-microrna-aktivitet
WO2007027775A2 (en)	2005-08-29	2007-03-08	Isis Pharmaceuticals, Inc.	Methods for use in modulating mir-122a
EP3000480A1 (de)	2005-12-01	2016-03-30	ProNAi Therapeutics, Inc.	Krebstherapien und dabei verwendete pharmazeutische zusammensetzungen
WO2007073149A1 (en)	2005-12-22	2007-06-28	Keygene N.V.	Alternative nucleotides for improved targeted nucleotide exchange
JP5713377B2 (ja)	2005-12-28	2015-05-07	ザスクリプスリサーチインスティテュート	薬物標的としての天然アンチセンスおよび非コードｒｎａ転写物
ES2351674T3 (es)	2006-01-27	2011-02-09	Isis Pharmaceuticals, Inc.	Análogos de ácidos nucleicos bicíclicos modificados en la posición 6.
US8129515B2 (en)	2006-01-27	2012-03-06	Isis Pharmaceuticals, Inc.	Oligomeric compounds and compositions for the use in modulation of microRNAs
CA2640423C (en)	2006-01-27	2016-03-15	Biogen Idec Ma Inc.	Nogo receptor antagonists
US7569686B1 (en)	2006-01-27	2009-08-04	Isis Pharmaceuticals, Inc.	Compounds and methods for synthesis of bicyclic nucleic acid analogs
AU2007229161B2 (en)	2006-03-23	2012-07-12	Roche Innovation Center Copenhagen A/S	Small internally segmented interfering RNA
EP2261333B1 (de)	2006-04-03	2016-03-30	Roche Innovation Center Copenhagen A/S	Pharmazeutische Zusammensetzung mit Anti-miRNA-Antisense-Oligonukleotiden
DK2666859T3 (en)	2006-04-03	2019-04-08	Roche Innovation Ct Copenhagen As	PHARMACEUTICAL COMPOSITION CONTAINING ANTI-miRNA ANTISENSE OLIGONUCLEOTIDES
EP2505648A1 (de)	2006-05-05	2012-10-03	Isis Pharmaceuticals, Inc.	Verbindungen und Verfahren zur Modulation der Expression von PTP1B
DK2021472T3 (da)	2006-05-05	2011-09-19	Isis Pharmaceuticals Inc	Forbindelser og fremgangsmåder til modulering af genekspression
US7666854B2 (en) *	2006-05-11	2010-02-23	Isis Pharmaceuticals, Inc.	Bis-modified bicyclic nucleic acid analogs
CA2651453C (en)	2006-05-11	2014-10-14	Isis Pharmaceuticals, Inc.	5'-modified bicyclic nucleic acid analogs
US20100062994A1 (en) *	2006-07-14	2010-03-11	Santaris Pharma A/S	Adenosine Receptor Antagonists
CA2667055C (en)	2006-10-18	2017-05-09	Isis Pharmaceuticals, Inc.	Antisense compounds
US8188255B2 (en)	2006-10-20	2012-05-29	Exiqon A/S	Human microRNAs associated with cancer
WO2008046911A2 (en)	2006-10-20	2008-04-24	Exiqon A/S	Novel human micrornas associated with cancer
EP2061901A2 (de)	2006-10-31	2009-05-27	Noxxon Pharma AG	Verfahren zum nachweis eines einzel- oder doppelsträngigen nukleinsäuremoleküls
WO2008060613A1 (en)	2006-11-15	2008-05-22	The J. David Gladstone Institutes	Methods and compositions for reducing amyloid beta levels
EP2455471A3 (de) *	2006-11-27	2012-09-12	Isis Pharmaceuticals, Inc.	Verfahren zur Behandlung von Hypercholesterinämie
US8093222B2 (en)	2006-11-27	2012-01-10	Isis Pharmaceuticals, Inc.	Methods for treating hypercholesterolemia
EP3536788A1 (de)	2006-12-21	2019-09-11	QIAGEN GmbH	Mikro-rna-zielortblockierende oligos und verwendungen davon
US8048998B2 (en)	2007-01-19	2011-11-01	Exiqon A/S	Mediated cellular delivery of LNA oligonucleotides
WO2009045469A2 (en)	2007-10-02	2009-04-09	Amgen Inc.	Increasing erythropoietin using nucleic acids hybridizable to micro-rna and precursors thereof
US20080206850A1 (en) *	2007-02-28	2008-08-28	Dellinger Douglas J	Methods and compositions for DNA synthesis
DK2149605T3 (da)	2007-03-22	2013-09-30	Santaris Pharma As	Korte RNA antagonist forbindelser til modulering af det ønskede mRNA
AU2008228243B2 (en)	2007-03-22	2014-05-15	Santaris Pharma A/S	RNA antagonist compounds for the inhibition of Apo-B100 expression
US8999634B2 (en)	2007-04-27	2015-04-07	Quest Diagnostics Investments Incorporated	Nucleic acid detection combining amplification with fragmentation
EP2170917B1 (de)	2007-05-30	2012-06-27	Isis Pharmaceuticals, Inc.	Über n-substituiertes aminomethylen verbrückte, bicyclische nukleinsäureanaloga
EP2173760B2 (de)	2007-06-08	2015-11-04	Isis Pharmaceuticals, Inc.	Carbozyklische bizyklische nukleinsäureanaloga
WO2008151631A2 (en) *	2007-06-15	2008-12-18	Exiqon A/S	Use of short oligonucleotides for reagent redundancy experiments in rna functional analysis
EP2176280B2 (de) *	2007-07-05	2015-06-24	Isis Pharmaceuticals, Inc.	6-disubstituierte bizyklische nukleinsäureanaloga
EP2198050A1 (de)	2007-09-14	2010-06-23	Asuragen, INC.	Mikrornas mit unterschiedlicher expression bei zervikalkarzinom und verwendungen davon
CN101849008A (zh)	2007-09-19	2010-09-29	应用生物系统有限公司	用于减少RNAi中的脱靶表型效应的siRNA的不依赖于序列的修饰形式和其稳定形式
ES2463665T3 (es)	2007-10-04	2014-05-28	Stella Aps	Tratamiento de combinación para el tratamiento de infección por virus de la hepatitis C
WO2009067647A1 (en) *	2007-11-21	2009-05-28	Isis Pharmaceuticals, Inc.	Carbocyclic alpha-l-bicyclic nucleic acid analogs
US10365224B2 (en)	2007-12-06	2019-07-30	Genalyte, Inc.	Label-free optical sensors
CA2708751A1 (en)	2007-12-14	2009-06-25	Minitube Of America, Inc.	Gender-specific separation of sperm cells and embryos
WO2009100320A2 (en) *	2008-02-07	2009-08-13	Isis Pharmaceuticals, Inc.	Bicyclic cyclohexitol nucleic acid analogs
EP2268811A1 (de)	2008-03-07	2011-01-05	Santaris Pharma A/S	Pharmazeutische zusammensetzungen zur behandlung von krankheiten in verbindung mit microrna
US8227431B2 (en)	2008-03-17	2012-07-24	Hetero Drugs Limited	Nucleoside derivatives
US8846639B2 (en) *	2008-04-04	2014-09-30	Isis Pharmaceutical, Inc.	Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity
WO2009124238A1 (en) *	2008-04-04	2009-10-08	Isis Pharmaceuticals, Inc.	Oligomeric compounds comprising neutrally linked terminal bicyclic nucleosides
WO2009123764A2 (en)	2008-04-04	2009-10-08	Calando Pharmaceuticals, Inc.	Compositions and use of epas1 inhibitors
US8258111B2 (en)	2008-05-08	2012-09-04	The Johns Hopkins University	Compositions and methods related to miRNA modulation of neovascularization or angiogenesis
US8222221B2 (en)	2008-06-04	2012-07-17	The Board Of Regents Of The University Of Texas System	Modulation of gene expression through endogenous small RNA targeting of gene promoters
CA2635187A1 (en)	2008-06-05	2009-12-05	The Royal Institution For The Advancement Of Learning/Mcgill University	Oligonucleotide duplexes and uses thereof
CA2732343C (en)	2008-07-29	2017-05-09	The Board Of Regents Of The University Of Texas System	Selective inhibition of polyglutamine protein expression
US8492357B2 (en)	2008-08-01	2013-07-23	Santaris Pharma A/S	Micro-RNA mediated modulation of colony stimulating factors
US20110237646A1 (en) *	2008-08-07	2011-09-29	Isis Pharmaceuticals, Inc.	Modulation of transthyretin expression for the treatment of cns related disorders
US8501805B2 (en) *	2008-09-24	2013-08-06	Isis Pharmaceuticals, Inc.	Substituted alpha-L-bicyclic nucleosides
CA2739464C (en) *	2008-10-03	2020-03-31	Curna, Inc.	Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoprotein-a1
EP2379084B1 (de)	2008-10-15	2017-11-22	Ionis Pharmaceuticals, Inc.	Modulation der expression von faktor 11
WO2010048585A2 (en)	2008-10-24	2010-04-29	Isis Pharmaceuticals, Inc.	Oligomeric compounds and methods
ES2939310T3 (es)	2008-10-27	2023-04-20	Genalyte Inc	Biosensores basados en sondeo y detección ópticos
MX2011005912A (es)	2008-12-04	2011-06-17	Opko Curna Llc	Tratamiento de enfermedades relacionadas con factor de crecimiento endotelial vascular por inhibicion de transcrito antisentido natural para factor de crecimiento endotelial vascular.
KR101829469B1 (ko)	2008-12-04	2018-03-30	큐알엔에이, 인크.	Ｅｐｏ에 대한 천연 안티센스 전사체의 억제에 의해 에리트로포에틴(ｅｐｏ) 관련된 질환의 치료
KR101866152B1 (ko)	2008-12-04	2018-06-08	큐알엔에이, 인크.	종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료
CN102257147A (zh)	2008-12-22	2011-11-23	凯津公司	在植物原生质体中使用双链rna提高靶基因改变的效率
US20120021515A1 (en)	2009-02-06	2012-01-26	Swayze Eric E	Oligomeric compounds and methods
WO2010093904A2 (en)	2009-02-12	2010-08-19	Curna, Inc.	Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
EP2408919B1 (de)	2009-03-16	2017-10-18	CuRNA, Inc.	Behandlung von erkrankungen im zusammenhang mit dem nuklearfaktor (erythroid-derived)-like 2 (nrf2) mittels hemmung des natürlichen antisense-transkripts gegen nrf2
EP2408920B1 (de)	2009-03-17	2017-03-08	CuRNA, Inc.	Behandlung von erkrankungen im zusammenhang mit dem delta-like-1-homolog (dlk1) mittels hemmung des natürlichen antisense-transkripts gegen dlk1
JP5773535B2 (ja)	2009-04-24	2015-09-02	ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブＲｏｃｈｅＩｎｎｏｖａｔｉｏｎＣｅｎｔｅｒＣｏｐｅｎｈａｇｅｎＡ／Ｓ	インターフェロンに非応答性のｈｃｖ患者の治療のための医薬組成物
US8815586B2 (en)	2009-04-24	2014-08-26	The Board Of Regents Of The University Of Texas System	Modulation of gene expression using oligomers that target gene regions downstream of 3′ untranslated regions
CN102459596B (zh)	2009-05-06	2016-09-07	库尔纳公司	通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
WO2010129746A2 (en)	2009-05-06	2010-11-11	Curna, Inc.	Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp
WO2010129861A2 (en)	2009-05-08	2010-11-11	Curna, Inc.	Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family
WO2010135329A2 (en)	2009-05-18	2010-11-25	Curna, Inc.	Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
CN102549158B (zh)	2009-05-22	2017-09-26	库尔纳公司	通过抑制针对转录因子e3(tfe3)的天然反义转录物来治疗tfe3和胰岛素受体底物蛋白2(irs2)相关的疾病
CA2764683A1 (en)	2009-05-28	2010-12-02	Joseph Collard	Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
CA2764158A1 (en)	2009-06-01	2010-12-09	Halo-Bio Rnai Therapeutics, Inc.	Polynucleotides for multivalent rna interference, compositions and methods of use thereof
CN102612560B (zh)	2009-06-16	2017-10-17	库尔纳公司	通过抑制针对对氧磷酶1(pon1)的天然反义转录物来治疗pon1相关的疾病
JP5944311B2 (ja)	2009-06-16	2016-07-05	クルナ・インコーポレーテッド	コラーゲン遺伝子に対する天然アンチセンス転写物の抑制によるコラーゲン遺伝子関連疾患の治療
CN115227709A (zh)	2009-06-17	2022-10-25	冷泉港实验室	用于在对象中调节smn2剪接的组合物和方法
US8859515B2 (en)	2009-06-24	2014-10-14	Curna, Inc.	Treatment of tumor necrosis factor receptor 2 (TNFR2) related diseases by inhibition of natural antisense transcript to TNFR2
CA2765815A1 (en)	2009-06-26	2010-12-29	Opko Curna, Llc	Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
US8563528B2 (en)	2009-07-21	2013-10-22	Santaris Pharma A/S	Antisense oligomers targeting PCSK9
US20120252869A1 (en)	2009-07-24	2012-10-04	Opko Curna, Llc	Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
JP6128848B2 (ja)	2009-08-05	2017-05-17	クルナ・インコーポレーテッド	インスリン遺伝子（ｉｎｓ）に対する天然アンチセンス転写物の抑制によるインスリン遺伝子（ｉｎｓ）関連疾患の治療
US9012421B2 (en)	2009-08-06	2015-04-21	Isis Pharmaceuticals, Inc.	Bicyclic cyclohexose nucleic acid analogs
CA2770104C (en)	2009-08-11	2019-03-19	Opko Curna, Llc	Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq)
WO2011022606A2 (en)	2009-08-21	2011-02-24	Curna, Inc.	Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip
KR101892760B1 (ko)	2009-08-25	2018-08-28	큐알엔에이, 인크.	ＩＱＧＡＰ에 대한 천연 안티센스 전사체의 억제에 의한 ＧＴＰａｓｅ 활성화 단백질을 함유하는 ＩＱ 모티프(ＩＱＧＡＰ)와 관련된 질환의 치료
US20110196141A1 (en) *	2009-09-07	2011-08-11	Council Of Scientific & Industrial Research	Locked and unlocked 2'-o phosphoramidite nucleosides, process of preparation thereof and oligomers comprising the nucleosides
WO2011032034A2 (en)	2009-09-10	2011-03-17	University Of Idaho	Nucleobase-functionalized conformationally restricted nucleotides and oligonucleotides for targeting nucleic acids
KR101802540B1 (ko)	2009-09-25	2017-11-28	큐알엔에이, 인크.	Ｆｌｇ의 발현 및 활성을 조절함으로써 필라그린(ｆｌｇ)에 관련된 질환의 치료
CN104928336B (zh)	2009-10-26	2020-05-08	弗·哈夫曼-拉罗切有限公司	用于生产糖基化免疫球蛋白的方法
WO2011053994A1 (en)	2009-11-02	2011-05-05	Alnylam Pharmaceuticals, Inc.	Modulation of ldl receptor gene expression with double-stranded rnas targeting the ldl receptor gene promoter
JP5991922B2 (ja)	2009-11-13	2016-09-14	サレプタセラピューティクス，インコーポレイテッド	アンチセンス抗ウイルス性化合物およびインフルエンザウイルス感染を処置するための方法
WO2011084455A2 (en)	2009-12-16	2011-07-14	Opko Curna, Llc.	Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1
JP6031356B2 (ja)	2009-12-23	2016-11-24	カッパーアールエヌエー，インコーポレイテッド	Ｕｃｐ２に対する天然アンチセンス転写産物の阻害による脱共役タンパク質２（ｕｃｐ２）関連疾患の治療
ES2661387T3 (es)	2009-12-23	2018-03-28	Curna, Inc.	Tratamiento de enfermedades relacionadas con el factor de crecimiento de hepatocitos (hgf) mediante inhibición del transcrito antisentido natural a hgf
KR101838305B1 (ko)	2009-12-29	2018-03-13	큐알엔에이, 인크.	ＮＲＦ1(ＮｕｃｌｅａｒＲｅｓｐｉｒａｔｏｒｙＦａｃｔｏｒ 1)에 대한 천연 안티센스 전사체의 억제에 의한 핵 호흡 인자 1 관련된 질환의 치료
US8962585B2 (en)	2009-12-29	2015-02-24	Curna, Inc.	Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63
DK2519632T3 (en)	2009-12-31	2018-07-23	Curna Inc	TREATMENT OF INSULIN RECEPTOR SUBSTRATE 2- (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPTION TO IRS2 AND TRANSCRIPTION FACTOR E3 (TFE3)
EP2521784B1 (de)	2010-01-04	2017-12-06	CuRNA, Inc.	Behandlung von erkrankungen im zusammenhang mit dem interferonregulierungsfaktor 8 (irf8) mittels hemmung des natürlichen antisense-transkripts gegen irf8
CN102822342B (zh)	2010-01-06	2017-05-10	库尔纳公司	通过抑制胰腺发育基因的天然反义转录物而治疗胰腺发育基因相关疾病
CN111700901A (zh)	2010-01-08	2020-09-25	Ionis制药公司	血管生成素样3表达的调节
WO2011085102A1 (en)	2010-01-11	2011-07-14	Isis Pharmaceuticals, Inc.	Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom
US9200277B2 (en)	2010-01-11	2015-12-01	Curna, Inc.	Treatment of sex hormone binding globulin (SHBG) related diseases by inhibition of natural antisense transcript to SHBG
EP2524038A4 (de) *	2010-01-12	2013-11-20	Isis Pharmaceuticals Inc	Modulation der transformierung einer wachstumsfaktor-beta-1-expression
CN102782135A (zh)	2010-01-25	2012-11-14	库尔纳公司	通过抑制rna酶h1的天然反义转录物而治疗rna酶h1相关疾病
WO2011097388A1 (en)	2010-02-03	2011-08-11	Alnylam Pharmaceuticals, Inc.	Selective inhibition of polyglutamine protein expression
EP2534262B1 (de)	2010-02-08	2016-12-14	Ionis Pharmaceuticals, Inc.	Selektive reduktion von allelvarianten
EP3561060A1 (de)	2010-02-08	2019-10-30	Ionis Pharmaceuticals, Inc.	Selektive reduktion von allelvarianten
WO2011103528A2 (en)	2010-02-22	2011-08-25	Opko Curna Llc	Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
WO2011105901A2 (en)	2010-02-23	2011-09-01	Academisch Ziekenhuis Bij De Universiteit Van Amsterdam	Antagonists of complement component 9 (c9) and uses thereof
WO2011105900A2 (en)	2010-02-23	2011-09-01	Academisch Ziekenhuis Bij De Universiteit Van Amsterdam	Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
WO2011105902A2 (en)	2010-02-23	2011-09-01	Academisch Ziekenhuis Bij De Universiteit Van Amsterdam	Antagonists of complement component 8-beta (c8-beta) and uses thereof
EP2539356A4 (de) *	2010-02-26	2014-03-05	Isis Pharmaceuticals Inc	Modulation der smad3-expression
WO2011112516A1 (en)	2010-03-08	2011-09-15	Ico Therapeutics Inc.	Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides
WO2011112732A2 (en)	2010-03-12	2011-09-15	The Brigham And Women's Hospital, Inc.	Methods of treating vascular inflammatory disorders
EP2545173A2 (de)	2010-03-12	2013-01-16	Sarepta Therapeutics, Inc.	Antisense-modulation von nukleären hormonrezeptoren
WO2011115818A1 (en)	2010-03-17	2011-09-22	Isis Pharmaceuticals, Inc.	5'-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom
CA2795145C (en)	2010-04-02	2019-01-22	Curna, Inc.	Treatment of colony-stimulating factor 3 (csf3) related diseases by inhibition of natural antisense transcript to csf3
AU2011237630B2 (en)	2010-04-06	2016-01-21	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of CD274/PD-L1 gene
KR101900962B1 (ko)	2010-04-09	2018-09-20	큐알엔에이, 인크.	섬유아세포 성장 인자 21 (ｆｇｆ21)에 대한 자연 안티센스 전사체의 저해에 의한 섬유아세포 성장 인자 21 (ｆｇｆ21) 관련된 질환의 치료
AU2011248625B2 (en)	2010-04-26	2017-01-05	Pangu Biopharma Limited	Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-tRNA synthetase
JP6294074B2 (ja)	2010-04-27	2018-03-14	エータイアーファーマ，インコーポレイテッド	イソロイシルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
EP2601204B1 (de)	2010-04-28	2016-09-07	Ionis Pharmaceuticals, Inc.	Modifizierte nukleoside und daraus hergestellte oligomere verbindungen
EP3091027B1 (de)	2010-04-28	2018-01-17	Ionis Pharmaceuticals, Inc.	5'-modifizierte nukleoside und daraus hergestellte oligomere verbindungen
CN103097524B (zh)	2010-04-28	2016-08-03	Atyr医药公司	与丙氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
US9156873B2 (en)	2010-04-28	2015-10-13	Isis Pharmaceuticals, Inc.	Modified 5′ diphosphate nucleosides and oligomeric compounds prepared therefrom
CA2797374C (en)	2010-04-29	2021-02-16	Pangu Biopharma Limited	Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl trna synthetases
HRP20170737T1 (hr)	2010-04-29	2017-07-28	Ionis Pharmaceuticals, Inc.	Modulacija ekspresije transtiretina
WO2011150279A2 (en)	2010-05-27	2011-12-01	Atyr Pharma, Inc.	Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-trna synthetases
AU2011248457B2 (en)	2010-04-29	2017-02-16	Pangu Biopharma Limited	Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl tRNA synthetases
US20130156845A1 (en)	2010-04-29	2013-06-20	Alnylam Pharmaceuticals, Inc.	Lipid formulated single stranded rna
EP2563935B1 (de)	2010-04-30	2014-04-16	Exiqon A/S	In-situ-hybridisierungsverfahren und puffer
WO2011139387A1 (en)	2010-05-03	2011-11-10	Opko Curna, Llc	Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
WO2011139986A2 (en)	2010-05-03	2011-11-10	Atyr Pharma, Inc.	Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-trna synthetases
WO2011140135A2 (en)	2010-05-03	2011-11-10	Atyr Pharma, Inc.	Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-trna synthetases
CA2797977C (en)	2010-05-03	2019-08-20	Atyr Pharma, Inc.	Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-trna synthetases
CA2798139C (en)	2010-05-04	2019-09-24	Atyr Pharma, Inc.	Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-trna synthetase complex
ES2816898T3 (es)	2010-05-13	2021-04-06	Sarepta Therapeutics Inc	Compuestos que modulan la actividad de señalización de las interleucinas 17 y 23
CN103200953B (zh)	2010-05-14	2017-02-15	Atyr 医药公司	与苯丙氨酰‑β‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
TWI531370B (zh)	2010-05-14	2016-05-01	可娜公司	藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
CN103096914B (zh)	2010-05-17	2015-08-12	Atyr医药公司	与亮氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
CA2799207C (en)	2010-05-26	2019-03-26	Curna, Inc.	Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1
RU2620978C2 (ru)	2010-05-26	2017-05-30	Курна, Инк.	Лечение заболеваний, связанных с метионинсульфоксидредуктазой а (msra), путем ингибирования природного антисмыслового транскрипта гена msra
US9944671B2 (en)	2010-06-02	2018-04-17	Alnylam Pharmaceuticals, Inc.	Compositions and methods directed to treating liver fibrosis
WO2011156278A1 (en)	2010-06-07	2011-12-15	Isis Pharmaceuticals, Inc.	Bicyclic nucleosides and oligomeric compounds prepared therefrom
WO2011156202A1 (en)	2010-06-08	2011-12-15	Isis Pharmaceuticals, Inc.	Substituted 2 '-amino and 2 '-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
EP2582397A4 (de)	2010-06-15	2014-10-29	Isis Pharmaceuticals Inc	Verbindungen und verfahren zur modulierung der interaktion zwischen proteinen und zielnukleinsäuren
KR101914309B1 (ko)	2010-06-23	2018-11-02	큐알엔에이, 인크.	전압 작동 나트륨 통로, 알파 소단위(scna)에 대한 자연 안티센스 전사체의 저해에 의한 전압 작동 나트륨 통로, 알파 소단위(scna) 관련된 질환의 치료
AU2011289831C1 (en)	2010-07-12	2017-06-15	Pangu Biopharma Limited	Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
NO2593547T3 (de)	2010-07-14	2018-04-14
EP3489360A3 (de)	2010-07-19	2019-08-28	Ionis Pharmaceuticals, Inc.	Modulation einer kern-rna
WO2012027206A1 (en)	2010-08-24	2012-03-01	Merck Sharp & Dohme Corp.	SINGLE-STRANDED RNAi AGENTS CONTAINING AN INTERNAL, NON-NUCLEIC ACID SPACER
CN103108650A (zh)	2010-08-25	2013-05-15	Atyr医药公司	与酪氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
CA2811333C (en) *	2010-09-16	2020-05-12	Gen-Probe Incorporated	Capture probes immobilizable via l-nucleotide tail
EP2619215B1 (de)	2010-09-22	2018-09-05	Alios Biopharma, Inc.	Azido-nukleoside und nukleotidanaloga
CA2813901C (en)	2010-10-06	2019-11-12	Curna, Inc.	Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4
CN103517990A (zh)	2010-10-07	2014-01-15	通用医疗公司	癌症生物标志物
US8648053B2 (en)	2010-10-20	2014-02-11	Rosalind Franklin University Of Medicine And Science	Antisense oligonucleotides that target a cryptic splice site in Ush1c as a therapeutic for Usher syndrome
JP6049623B2 (ja)	2010-10-22	2016-12-21	カッパーアールエヌエー，インコーポレイテッド	α‐Ｌ‐イズロニダーゼ（ＩＤＵＡ）への天然アンチセンス転写物の阻害によるＩＤＵＡ関連疾患の治療
EP3766975A1 (de)	2010-10-29	2021-01-20	Sirna Therapeutics, Inc.	Rna-interferenz-vermittelte inhibition von genexpression unter verwendung kurzer interferierender nukleinsäure (sina)
EP3733866B1 (de)	2010-11-05	2023-11-15	Genalyte, Inc.	Systeme zur optischen analytdetektion und verfahren zur verwendung
US9150864B2 (en)	2010-11-08	2015-10-06	Isis Pharmaceuticals, Inc.	Methods for modulating factor 12 expression
AU2011325956B2 (en)	2010-11-12	2016-07-14	The General Hospital Corporation	Polycomb-associated non-coding RNAs
WO2012068405A2 (en)	2010-11-17	2012-05-24	Isis Pharmaceuticals, Inc.	Modulation of alpha synuclein expression
US10000752B2 (en)	2010-11-18	2018-06-19	Curna, Inc.	Antagonat compositions and methods of use
WO2012071238A2 (en)	2010-11-23	2012-05-31	Opko Curna Llc	Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog
JP5947309B2 (ja)	2010-12-02	2016-07-06	キージーン・エン・フェー	オリゴヌクレオチドを用いたｄｎａの標的改変
CA2819423C (en)	2010-12-02	2020-12-22	Keygene N.V.	Targeted alteration of dna
EP2648763A4 (de)	2010-12-10	2014-05-14	Alnylam Pharmaceuticals Inc	Zusammensetzungen und verfahren zur expressionshemmung der gene klf-1 und bcl11a
US9193973B2 (en)	2010-12-10	2015-11-24	Alynylam Pharmaceuticals, Inc.	Compositions and methods for increasing erythropoietin (EPO) production
EP2663323B1 (de)	2011-01-14	2017-08-16	The General Hospital Corporation	Verfahren zur anzielung von mir-128 zur regelung des cholesterin-/fettstoffwechsels
EP3067421B1 (de)	2011-02-08	2018-10-10	Ionis Pharmaceuticals, Inc.	Oligomere verbindungen mit bicyclischen nukleotiden und verwendungen davon
MX360349B (es)	2011-03-29	2018-10-30	Alnylam Pharmaceuticals Inc	Composiciones y metodos para inhibir la expresion del gen de proteasa transmembrana, serina 6 (tmprss6).
RS58489B1 (sr)	2011-04-01	2019-04-30	Ionis Pharmaceuticals Inc	Modulacija eksprimiranja transduktora signala i aktivatora transkripcije 3 (stat3)
CN105886506A (zh)	2011-04-13	2016-08-24	Isis制药公司	Ptp1b 表达的反义调节
US8642752B2 (en)	2011-04-21	2014-02-04	Isis Pharmaceuticals, Inc.	Modulation of Hepatitis B virus (HBV) expression
US9157082B2 (en)	2011-04-27	2015-10-13	Isis Pharmaceuticals, Inc.	Modulation of apolipoprotein CIII (ApoCIII) expression
WO2012151324A1 (en)	2011-05-02	2012-11-08	Isis Pharmaceuticals, Inc.	Antisense compounds targeting genes associated with usher syndrome
WO2012170347A1 (en)	2011-06-09	2012-12-13	Isis Pharmaceuticals, Inc.	Bicyclic nucleosides and oligomeric compounds prepared therefrom
RU2620980C2 (ru)	2011-06-09	2017-05-30	Курна, Инк.	Лечение заболеваний, связанных с фратаксином (fxn), путем ингибирования природного антисмыслового транскрипта fxn
US9315811B2 (en)	2011-06-10	2016-04-19	Ionis Pharmaceuticals, Inc.	Methods for modulating kallikrein (KLKB1) expression
US9187749B2 (en)	2011-06-10	2015-11-17	Isis Pharmaceuticals, Inc.	Methods for modulating factor 12 expression
CA2839437A1 (en)	2011-06-16	2012-12-20	Isis Pharmaceuticals, Inc.	Antisense modulation of fibroblast growth factor receptor 4 expression
EP3444348A1 (de)	2011-06-21	2019-02-20	Alnylam Pharmaceuticals, Inc.	Angiopoietin-3 (angptl3)-irna-zusammensetzungen und verfahren zur verwendung davon
WO2012178033A2 (en)	2011-06-23	2012-12-27	Alnylam Pharmaceuticals, Inc.	Serpina1 sirnas: compositions of matter and methods of treatment
AU2012275096B2 (en)	2011-06-29	2016-02-04	Ionis Pharmaceuticals, Inc.	Methods for modulating kallikrein (KLKB1) expression
EP2732035A2 (de)	2011-07-15	2014-05-21	Sarepta Therapeutics, Inc.	Verfahren und zusammensetzungen zur manipulation der übersetzung von proteinisoformen aus alternativen initiierungsstellen
WO2013013068A2 (en)	2011-07-19	2013-01-24	University Of Idaho	Embodiments of a probe and method for targeting nucleic acids
WO2013019857A2 (en)	2011-08-01	2013-02-07	Alnylam Pharmaceuticals, Inc.	Method for improving the success rate of hematopoietic stem cell transplants
US10202599B2 (en)	2011-08-11	2019-02-12	Ionis Pharmaceuticals, Inc.	Selective antisense compounds and uses thereof
EP3640332A1 (de)	2011-08-29	2020-04-22	Ionis Pharmaceuticals, Inc.	Oligomer-konjugat-komplexe und deren verwendung
EP2751269B1 (de)	2011-08-29	2016-03-23	Ionis Pharmaceuticals, Inc.	Verfahren und verbindungen für erkrankungen im zusammenhang mit repeat-expansion
US10583128B2 (en)	2011-09-06	2020-03-10	Curna, Inc.	Treatment of diseases related to alpha subunits of sodium channels, voltage-gated (SCNxA) with small molecules
WO2013040251A2 (en)	2011-09-13	2013-03-21	Asurgen, Inc.	Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease
EP2758533B1 (de)	2011-09-20	2018-04-11	Ionis Pharmaceuticals, Inc.	Antisense-modulation der gcgr-expression
US20130085139A1 (en)	2011-10-04	2013-04-04	Royal Holloway And Bedford New College	Oligomers
EP2766482B1 (de)	2011-10-11	2016-12-07	The Brigham and Women's Hospital, Inc.	Mikro-rnas in neurodegenerativen erkrankungen
WO2013059740A1 (en)	2011-10-21	2013-04-25	Foundation Medicine, Inc.	Novel alk and ntrk1 fusion molecules and uses thereof
WO2013063313A1 (en)	2011-10-25	2013-05-02	Isis Pharmaceuticals, Inc.	Antisense modulation of gccr expression
EP2773777B1 (de)	2011-10-31	2020-05-13	University of Utah Research Foundation	Genetische veränderungen bei glioblastomen
WO2013070786A1 (en)	2011-11-07	2013-05-16	Isis Pharmaceuticals, Inc.	Modulation of tmprss6 expression
US9243291B1 (en)	2011-12-01	2016-01-26	Isis Pharmaceuticals, Inc.	Methods of predicting toxicity
WO2013086441A2 (en)	2011-12-08	2013-06-13	Sarepta Therapeutics, Inc.	Oligonucleotide analogues targeting human lmna
JP2015501844A (ja)	2011-12-16	2015-01-19	モデルナセラピューティクスインコーポレイテッドＭｏｄｅｒｎａＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	修飾ヌクレオシド、ヌクレオチドおよび核酸組成物
JP6280045B2 (ja)	2011-12-22	2018-02-14	アイオーニスファーマシューティカルズ，インコーポレーテッドＩｏｎｉｓＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	肺腺癌内転移関連性転写物１（ｍｅｔａｓｔａｓｉｓ−ａｓｓｏｃｉａｔｅｄ−ｉｎ−ｌｕｎｇ−ａｄｅｎｏｃａｒｃｉｎｏｍａ−ｔｒａｎｓｃｒｉｐｔ−１：ｍａｌａｔ−１）の発現調節法
SG10201610936RA (en)	2011-12-22	2017-02-27	Alios Biopharma Inc	Substituted nucleosides, nucleotides and analogs thereof
EP2797948B1 (de)	2011-12-27	2019-02-20	The J. David Gladstone Institutes	Zusammensetzungen zur verwendung in der regulierung des glukosemetabolismus
WO2013106770A1 (en)	2012-01-11	2013-07-18	Isis Pharmaceuticals, Inc.	Compositions and methods for modulation of ikbkap splicing
EP3330278A1 (de)	2012-02-08	2018-06-06	Ionis Pharmaceuticals, Inc.	Modulation von rna durch wiederholtes targeting
EP2825885B1 (de)	2012-03-12	2021-05-12	The Board of Trustees of the University of Illinois	Optische analytdetektionssysteme mit magnetischer verstärkung
EP2825648B1 (de)	2012-03-15	2018-09-05	CuRNA, Inc.	Behandlung von erkrankungen im zusammenhang mit dem brain-derived neurotrophen faktor (bdnf) mittels hemmung des natürlichen antisense-transkripts gegen bdnf
WO2013142514A1 (en)	2012-03-19	2013-09-26	Isis Pharmaceuticals, Inc.	Methods and compositions for modulating alpha-1-antitrypsin expression
US9441007B2 (en)	2012-03-21	2016-09-13	Alios Biopharma, Inc.	Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en)	2012-03-21	2020-08-25	Janssen Biopharma, Inc.	Substituted nucleosides, nucleotides and analogs thereof
WO2013148283A1 (en)	2012-03-30	2013-10-03	Isis Pharmaceuticals, Inc.	Compositions and methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome
CN108949772A (zh)	2012-04-02	2018-12-07	现代泰克斯公司	用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸
WO2013151663A1 (en)	2012-04-02	2013-10-10	modeRNA Therapeutics	Modified polynucleotides for the production of membrane proteins
WO2013154799A1 (en) *	2012-04-09	2013-10-17	Isis Pharmaceuticals, Inc.	Tricyclic nucleosides and oligomeric compounds prepared therefrom
EP2850092B1 (de)	2012-04-09	2017-03-01	Ionis Pharmaceuticals, Inc.	Tricyclische nukleinsäureanaloga
US9133461B2 (en)	2012-04-10	2015-09-15	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the ALAS1 gene
EP2839006B1 (de)	2012-04-20	2018-01-03	Ionis Pharmaceuticals, Inc.	Oligomere verbindungen mit bicyclischen nukleotiden und verwendungen davon
US9127274B2 (en)	2012-04-26	2015-09-08	Alnylam Pharmaceuticals, Inc.	Serpinc1 iRNA compositions and methods of use thereof
WO2013163628A2 (en)	2012-04-27	2013-10-31	Duke University	Genetic correction of mutated genes
US9574193B2 (en)	2012-05-17	2017-02-21	Ionis Pharmaceuticals, Inc.	Methods and compositions for modulating apolipoprotein (a) expression
WO2013173789A2 (en)	2012-05-17	2013-11-21	Isis Pharmaceuticals, Inc.	Antisense oligonucleotide compositions
WO2013177248A2 (en)	2012-05-22	2013-11-28	Isis Pharmaceuticals, Inc.	Modulation of enhancer rna mediated gene expression
HUE051680T2 (hu)	2012-05-24	2021-03-29	Ionis Pharmaceuticals Inc	Apolipoprotein(a) expressziójának módosítására szolgáló eljárások és készítmények
HUE029038T2 (en)	2012-05-25	2017-01-30	Janssen Sciences Ireland Uc	Uracil spirooxetan nucleosides
WO2013184209A1 (en)	2012-06-04	2013-12-12	Ludwig Institute For Cancer Research Ltd.	Mif for use in methods of treating subjects with a neurodegenerative disorder
JP6294876B2 (ja)	2012-06-25	2018-03-14	アイオーニスファーマシューティカルズ，インコーポレーテッドＩｏｎｉｓＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	Ｕｂｅ３ａ−ａｔｓ発現の調節
ES2773489T3 (es)	2012-07-27	2020-07-13	Ionis Pharmaceuticals Inc	Modulación de enfermedades relacionadas con el sistema renina-angiotensina (RAS) mediante angiotensinógenos
US9403865B2 (en)	2012-08-15	2016-08-02	Ionis Pharmaceuticals, Inc.	Method of preparing oligomeric compounds using modified capping protocols
WO2014045126A2 (en)	2012-09-18	2014-03-27	Uti Limited Partnership	Treatment of pain by inhibition of usp5 de-ubiquitinase
WO2014059353A2 (en)	2012-10-11	2014-04-17	Isis Pharmaceuticals, Inc.	Oligomeric compounds comprising bicyclic nucleosides and uses thereof
EP4052709A1 (de)	2012-10-11	2022-09-07	Ionis Pharmaceuticals, Inc.	Verfahren zur behandlung der kennedy-krankheit
AR092982A1 (es)	2012-10-11	2015-05-13	Isis Pharmaceuticals Inc	Modulacion de la expresion de receptores androgenicos
US20150275208A1 (en)	2012-10-12	2015-10-01	Isis Pharmaceuticals, Inc.	Selective antisense compounds and uses thereof
WO2014059341A2 (en)	2012-10-12	2014-04-17	Isis Pharmaceuticals, Inc.	Antisense compounds and uses thereof
RU2730677C2 (ru)	2012-10-15	2020-08-24	Ионис Фармасьютикалз, Инк.	Соединение для модуляции экспрессии гена c9orf72 и его применение
US9963699B2 (en)	2012-10-15	2018-05-08	Ionis Pharmaceuticals, Inc.	Methods for modulating C9ORF72 expression
WO2014062736A1 (en)	2012-10-15	2014-04-24	Isis Pharmaceuticals, Inc.	Methods for monitoring c9orf72 expression
US9029335B2 (en)	2012-10-16	2015-05-12	Isis Pharmaceuticals, Inc.	Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
WO2014070868A1 (en)	2012-10-31	2014-05-08	Isis Pharmaceuticals Inc	Cancer treatment
AU2013337277B2 (en)	2012-11-05	2018-03-08	Foundation Medicine, Inc.	Novel NTRK1 fusion molecules and uses thereof
WO2014071419A2 (en)	2012-11-05	2014-05-08	Foundation Medicine, Inc.	Novel fusion molecules and uses thereof
CN104884637A (zh)	2012-11-05	2015-09-02	普隆奈治疗公司	利用生物标志物通过bcl2表达的调节治疗癌症的方法
SG10201804331TA (en)	2012-11-15	2018-07-30	Roche Innovation Ct Copenhagen As	Oligonucleotide conjugates
CA2889993A1 (en)	2012-11-26	2014-05-30	Roche Innovation Center Copenhagen A/S	Compositions and methods for modulation of fgfr3 expression
ES2921623T3 (es)	2012-11-26	2022-08-30	Modernatx Inc	ARN modificado terminalmente
WO2014093537A1 (en)	2012-12-11	2014-06-19	Isis Pharmaceuticals, Inc.	Competitive modulation of micrornas
GEP201706757B (en)	2012-12-21	2017-10-25	Alios Biopharma Inc	Substituted nucleosides, nucleotides and analogs thereof
WO2014110291A1 (en)	2013-01-09	2014-07-17	Isis Pharmaceuticals, Inc.	Compositions and methods for modulation of smn2 splicing in a subject
JP2016504050A (ja)	2013-01-17	2016-02-12	モデルナセラピューティクスインコーポレイテッドＭｏｄｅｒｎａＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	細胞表現型の改変のためのシグナルセンサーポリヌクレオチド
WO2014113729A2 (en)	2013-01-18	2014-07-24	Foundation Mecicine, Inc.	Methods of treating cholangiocarcinoma
WO2014118272A1 (en)	2013-01-30	2014-08-07	Santaris Pharma A/S	Antimir-122 oligonucleotide carbohydrate conjugates
US20150368642A1 (en)	2013-01-30	2015-12-24	Hoffmann-La Roche Inc.	Lna oligonucleotide carbohydrate conjugates
US9701708B2 (en)	2013-01-31	2017-07-11	Ionis Pharmaceuticals, Inc.	Method of preparing oligomeric compounds using modified coupling protocols
US10260069B2 (en)	2013-02-04	2019-04-16	Ionis Pharmaceuticals, Inc.	Selective antisense compounds and uses thereof
KR102169899B1 (ko)	2013-02-14	2020-10-26	아이오니스 파마수티컬즈, 인코포레이티드	지질단백질 리파제 결핍 (lpld) 모집단에서 아포지질단백질 c-iii (apociii) 발현의 조절
US20150366890A1 (en)	2013-02-25	2015-12-24	Trustees Of Boston University	Compositions and methods for treating fungal infections
EP2961853B1 (de)	2013-02-28	2018-09-19	The Board of Regents of The University of Texas System	Verfahren zur klassifizierung einer krebserkrankung als anfälligkeit für tmepai-gerichtete therapien und zur heilung solcher krebserkrankungen
WO2014134144A1 (en)	2013-02-28	2014-09-04	The General Hospital Corporation	Mirna profiling compositions and methods of use
US20160024181A1 (en)	2013-03-13	2016-01-28	Moderna Therapeutics, Inc.	Long-lived polynucleotide molecules
US9273349B2 (en)	2013-03-14	2016-03-01	Affymetrix, Inc.	Detection of nucleic acids
US10258698B2 (en)	2013-03-14	2019-04-16	Modernatx, Inc.	Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
CN111254145A (zh)	2013-03-14	2020-06-09	Ionis制药公司	用于调节tau表达的组合物和方法
ME03043B (de)	2013-03-14	2018-10-20	Alnylam Pharmaceuticals Inc	Gegen komplementkomponente c5 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon
US8980864B2 (en)	2013-03-15	2015-03-17	Moderna Therapeutics, Inc.	Compositions and methods of altering cholesterol levels
US9983206B2 (en)	2013-03-15	2018-05-29	The Board Of Trustees Of The University Of Illinois	Methods and compositions for enhancing immunoassays
US9828582B2 (en)	2013-03-19	2017-11-28	Duke University	Compositions and methods for the induction and tuning of gene expression
US10590412B2 (en)	2013-04-19	2020-03-17	Ionis Pharmaceuticals, Inc.	Compositions and methods for modulation nucleic acids through nonsense mediated decay
CA2921162A1 (en)	2013-05-01	2014-11-06	Ionis Pharmaceuticals, Inc.	Conjugated antisense compounds and their use
EA201592225A1 (ru)	2013-05-22	2016-04-29	Элнилэм Фармасьютикалз, Инк.	КОМПОЗИЦИИ НА ОСНОВЕ iRNA TMPRSS6 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
KR102463973B1 (ko)	2013-05-22	2022-11-07	알닐람 파마슈티칼스 인코포레이티드	ＳＥＲＰＩＮＡ1 ｉＲＮＡ 조성물 및 이의 사용 방법
WO2014197835A2 (en)	2013-06-06	2014-12-11	The General Hospital Corporation	Methods and compositions for the treatment of cancer
JP6694382B2 (ja)	2013-06-21	2020-05-13	アイオーニスファーマシューティカルズ，インコーポレーテッドＩｏｎｉｓＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	標的核酸を調節するための組成物および方法
EP3011026B1 (de)	2013-06-21	2019-12-18	Ionis Pharmaceuticals, Inc.	Verbindungen und verfahren zur modulation der apolipoprotein-c-iii-expression zur verbesserung eines diabetischen profils
AU2014300981B2 (en)	2013-06-27	2017-08-10	Ricc A/S	Antisense oligomers and conjugates targeting PCSK9
ES2787600T3 (es)	2013-07-02	2020-10-16	Ionis Pharmaceuticals Inc	Moduladores del receptor de la hormona del crecimiento
HUE056760T2 (hu)	2013-07-11	2022-03-28	Modernatx Inc	A CRISPR-hez kapcsolódó fehérjéket és a szintetikus SGRNS-ket kódoló szintetikus polinukleotidokat tartalmazó készítmények és felhasználási módjaik
JP6617702B2 (ja)	2013-07-15	2019-12-11	ザリージェンツオブザユニバーシティオブカリフォルニア	Ｆｔｙ７２０のアザサイクリック拘束アナログ
TWI657819B (zh)	2013-07-19	2019-05-01	美商Ionis製藥公司	用於調節τ蛋白表現之組合物
WO2015017675A2 (en)	2013-07-31	2015-02-05	Isis Pharmaceuticals, Inc.	Methods and compounds useful in conditions related to repeat expansion
RS59991B1 (sr)	2013-08-08	2020-04-30	Scripps Research Inst	Metoda enzimskog in vitro obeležavanja specifičnog za položaj nukleinskih kiselina uvođenjem neprirodnih nukleotida
TW201536329A (zh)	2013-08-09	2015-10-01	Isis Pharmaceuticals Inc	用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法
KR102365486B1 (ko)	2013-08-28	2022-02-18	아이오니스 파마수티컬즈, 인코포레이티드	프리칼리크레인 (pkk) 발현의 조절
US20160194625A1 (en)	2013-09-03	2016-07-07	Moderna Therapeutics, Inc.	Chimeric polynucleotides
WO2015034925A1 (en)	2013-09-03	2015-03-12	Moderna Therapeutics, Inc.	Circular polynucleotides
KR102275504B1 (ko)	2013-09-05	2021-07-09	사렙타 쎄러퓨틱스, 인코퍼레이티드	산성 알파-글루코시다제 내 안티센스-유도된 엑손2 포함
JP6666250B2 (ja)	2013-09-13	2020-03-13	アイオーニスファーマシューティカルズ，インコーポレーテッドＩｏｎｉｓＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	補体ｂ因子の調節薬
US9943604B2 (en)	2013-09-20	2018-04-17	Ionis Pharmaceuticals, Inc.	Targeted therapeutic nucleosides and their use
CA2925107A1 (en)	2013-10-02	2015-04-09	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the lect2 gene
KR20160067219A (ko)	2013-10-03	2016-06-13	모더나 세라퓨틱스, 인코포레이티드	저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
SG11201602631XA (en)	2013-10-04	2016-05-30	Alnylam Pharmaceuticals Inc	Compositions and methods for inhibiting expression of the alas1 gene
SG10201808903UA (en)	2013-10-11	2018-11-29	Ionis Pharmaceuticals Inc	Compositions for modulating c9orf72 expression
US11162096B2 (en)	2013-10-14	2021-11-02	Ionis Pharmaceuticals, Inc	Methods for modulating expression of C9ORF72 antisense transcript
WO2015061246A1 (en)	2013-10-21	2015-04-30	Isis Pharmaceuticals, Inc.	Method for solution phase detritylation of oligomeric compounds
EP3060680B1 (de)	2013-10-21	2019-02-27	The General Hospital Corporation	Verfahren im zusammenhang mit zirkulierenden tumorzellclustern und krebsbehandlung
WO2015075166A1 (en)	2013-11-22	2015-05-28	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for treatment of a bacterial infection
EP3077510B1 (de)	2013-12-02	2020-05-06	Ionis Pharmaceuticals, Inc.	Antisense-verbindungen und verwendungen davon
CA2931090A1 (en)	2013-12-12	2015-06-18	Alnylam Pharmaceuticals, Inc.	Complement component irna compositions and methods of use thereof
AU2014364520B2 (en)	2013-12-20	2020-01-02	The General Hospital Corporation	Methods and assays relating to circulating tumor cells
HUE052243T2 (hu)	2013-12-24	2021-04-28	Ionis Pharmaceuticals Inc	Az angiopoietin-szerû 3 expressziójának modulációja
US9765332B2 (en)	2014-01-29	2017-09-19	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Oligonucleotides and methods for inhibiting or reducing bacterial biofilms
AU2015217301A1 (en)	2014-02-11	2016-08-25	Alnylam Pharmaceuticals, Inc.	Ketohexokinase (KHK) iRNA compositions and methods of use thereof
WO2015142910A1 (en)	2014-03-17	2015-09-24	Isis Pharmaceuticals, Inc.	Bicyclic carbocyclic nucleosides and oligomeric compounds prepared therefrom
CN116970607A (zh)	2014-03-19	2023-10-31	Ionis制药公司	用于调节共济失调蛋白2表达的组合物
WO2015143245A1 (en)	2014-03-19	2015-09-24	Isis Pharmaceuticals, Inc.	Methods for modulating ataxin 2 expression
MY192634A (en)	2014-04-01	2022-08-29	Biogen Ma Inc	Compositions for modulating sod-1 expression
TWI638047B (zh)	2014-04-09	2018-10-11	史基普研究協會	藉由核酸三磷酸酯轉運子將非天然或經修飾的核苷三磷酸酯輸入至細胞中
MA39835A (fr)	2014-04-17	2017-02-22	Biogen Ma Inc	Compositions et procédés de modulation de l'épissage du smn2 chez un patient
US10221416B2 (en)	2014-04-24	2019-03-05	Ionis Pharmaceuticals, Inc.	Oligomeric compounds comprising alpha-beta-constrained nucleic acid
WO2015168172A1 (en)	2014-04-28	2015-11-05	Isis Pharmaceuticals, Inc.	Linkage modified oligomeric compounds
AU2015252841B2 (en)	2014-05-01	2020-03-19	Ionis Pharmaceuticals, Inc.	Compositions and methods for modulating growth hormone receptor expression
US10280423B2 (en)	2014-05-01	2019-05-07	Ionis Pharmaceuticals, Inc.	Compositions and methods for modulating complement factor B expression
JP6665111B2 (ja)	2014-05-01	2020-03-13	アイオーニスファーマシューティカルズ，インコーポレーテッドＩｏｎｉｓＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	Ｐｋｋ発現を調節するための組成物及び方法
MX382230B (es)	2014-05-01	2025-03-13	Ionis Pharmaceuticals Inc	Composiciones y metodos para modular la expresion de similar a la angiopoyetina tipo 3.
WO2015168514A1 (en)	2014-05-01	2015-11-05	Isis Pharmaceuticals, Inc.	Method for synthesis of reactive conjugate clusters
WO2015175510A1 (en)	2014-05-12	2015-11-19	Alnylam Pharmaceuticals, Inc.	Methods and compositions for treating a serpinc1-associated disorder
BR122020023687B1 (pt)	2014-05-22	2023-03-07	Alnylam Pharmaceuticals, Inc	Agente de ácido ribonucleico (rnai) de fita dupla, seus usos e composição farmacêutica
US10570169B2 (en)	2014-05-22	2020-02-25	Ionis Pharmaceuticals, Inc.	Conjugated antisense compounds and their use
CN106659758A (zh)	2014-06-02	2017-05-10	儿童医疗中心有限公司	用于免疫调节的组合物和方法
GB201410693D0 (en)	2014-06-16	2014-07-30	Univ Southampton	Splicing modulation
EP3760208B1 (de)	2014-06-25	2024-05-29	The General Hospital Corporation	Targeting von humanem satellit ii (hsatii)
EP3169693B1 (de)	2014-07-16	2022-03-09	ModernaTX, Inc.	Chimäre polynukleotide
WO2016014846A1 (en)	2014-07-23	2016-01-28	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of intrabodies
ES2832748T3 (es)	2014-08-19	2021-06-11	Hoffmann La Roche	Procedimientos y composiciones para la detección de ácidos nucleicos
ES2985036T3 (es)	2014-08-29	2024-11-04	Childrens Medical Ct Corp	Métodos y composiciones para el tratamiento del cáncer
EP3191591A1 (de)	2014-09-12	2017-07-19	Alnylam Pharmaceuticals, Inc.	Gegen komplementkomponente c5 gerichtete polynukleotidwirkstoffe und verfahren zur verwendung davon
WO2016040748A1 (en)	2014-09-12	2016-03-17	Ionis Pharmaceuticals, Inc.	Compositions and methods for detection of smn protein in a subject and treatment of a subject
EP3201350B1 (de) *	2014-09-30	2020-12-02	Global Life Sciences Solutions USA LLC	Verfahren zur nukleinsäureanalyse direkt aus einer ungereinigten biologischen probe
EP3201339A4 (de)	2014-10-03	2018-09-19	Cold Spring Harbor Laboratory	Gezielten erhöhung der nukleären genleistung
TWI864340B (zh)	2014-10-10	2024-12-01	美商艾爾妮蘭製藥公司	用於抑制hao1(羥酸氧化酶1(乙醇酸鹽氧化酶))基因表現的組合物及方法
WO2016061131A1 (en)	2014-10-14	2016-04-21	The J. David Gladstone Institutes	Compositions and methods for reactivating latent immunodeficiency virus
EP3207138B1 (de)	2014-10-17	2020-07-15	Alnylam Pharmaceuticals, Inc.	Gegen aminolävulinsäuresynthase-1 (alas1) gerichtete polynukleotidmittel und verwendungen davon
EP3904519A1 (de)	2014-10-30	2021-11-03	Genzyme Corporation	Polynukleotidwirkstoffe mit abzielung auf serpinc1 (at3) und verfahren zur verwendung davon
SG11201703638XA (en)	2014-11-10	2017-06-29	Alnylam Pharmaceuticals Inc	Hepatitis b virus (hbv) irna compositions and methods of use thereof
AU2015346042A1 (en)	2014-11-14	2017-04-27	Ionis Pharmaceuticals, Inc.	Compounds and methods for the modulation of proteins
WO2016077704A1 (en)	2014-11-14	2016-05-19	The Regents Of The University Of California	Modulation of agpat5 expression
CA2968114A1 (en)	2014-11-17	2016-05-26	Alnylam Pharmaceuticals, Inc.	Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
EP3221445B1 (de)	2014-11-20	2021-07-14	The Regents of The University of California	Zusammensetzungen und verfahren in zusammenhang mit hämatologischer erholung
US10400243B2 (en)	2014-11-25	2019-09-03	Ionis Pharmaceuticals, Inc.	Modulation of UBE3A-ATS expression
EP3229842B1 (de)	2014-12-08	2022-07-06	The Board of Regents of The University of Texas System	Lipokationische polymere und verwendungen davon
ES2810375T3 (es)	2014-12-17	2021-03-08	Proqr Therapeutics Ii Bv	Edición direccionada de ARN
EP3234141A4 (de)	2014-12-18	2018-06-20	Alnylam Pharmaceuticals, Inc.	Reversir-tm-verbindungen
US9688707B2 (en)	2014-12-30	2017-06-27	Ionis Pharmaceuticals, Inc.	Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
WO2016112132A1 (en)	2015-01-06	2016-07-14	Ionis Pharmaceuticals, Inc.	Compositions for modulating expression of c9orf72 antisense transcript
WO2016115490A1 (en)	2015-01-16	2016-07-21	Ionis Pharmaceuticals, Inc.	Compounds and methods for modulation of dux4
JP6929791B2 (ja)	2015-02-09	2021-09-01	デュークユニバーシティ	エピゲノム編集のための組成物および方法
WO2016130806A2 (en)	2015-02-13	2016-08-18	Alnylam Pharmaceuticals, Inc.	Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
US10426789B2 (en)	2015-02-26	2019-10-01	Ionis Pharmaceuticals, Inc.	Allele specific modulators of P23H rhodopsin
WO2016141145A1 (en)	2015-03-03	2016-09-09	Ionis Pharmaceuticals, Inc.	Methods for modulating mecp2 expression
US11129844B2 (en)	2015-03-03	2021-09-28	Ionis Pharmaceuticals, Inc.	Compositions and methods for modulating MECP2 expression
EP4636085A3 (de)	2015-03-03	2026-01-07	Ionis Pharmaceuticals, Inc.	Zusammensetzungen zur modulierung der mecp2-expression
MA41795A (fr)	2015-03-18	2018-01-23	Sarepta Therapeutics Inc	Exclusion d'un exon induite par des composés antisens dans la myostatine
HK1249140A1 (zh)	2015-04-03	2018-10-26	Ionis Pharmaceuticals, Inc.	用於调节tmprss6表达的化合物和方法
US10961532B2 (en)	2015-04-07	2021-03-30	The General Hospital Corporation	Methods for reactivating genes on the inactive X chromosome
MX2017012610A (es)	2015-04-08	2018-03-16	Alnylam Pharmaceuticals Inc	Composiciones y metodos para inhibir la expresion del gen lect2.
WO2016167780A1 (en)	2015-04-16	2016-10-20	Ionis Pharmaceuticals, Inc.	Compositions for modulating expression of c9orf72 antisense transcript
SI3283080T1 (sl)	2015-04-16	2020-06-30	Ionis Pharmaceuticals, Inc.	Sestavki za moduliranje izražanja C9ORF72
US10849917B2 (en)	2015-06-01	2020-12-01	Sarepta Therapeutics, Inc.	Antisense-induced exon exclusion in type VII collagen
WO2016201301A1 (en)	2015-06-12	2016-12-15	Alnylam Pharmaceuticals, Inc.	Complement component c5 irna compositions and methods of use thereof
EP3310918B1 (de)	2015-06-18	2020-08-05	Alnylam Pharmaceuticals, Inc.	Gegen hydroxysäureoxidase (glycolat-oxidase, hao1) gerichtete polynukleotidwirkstoffe und verfahren zur verwendung davon
WO2016209862A1 (en)	2015-06-23	2016-12-29	Alnylam Pharmaceuticals, Inc.	Glucokinase (gck) irna compositions and methods of use thereof
CA2990852A1 (en)	2015-06-26	2016-12-29	Beth Israel Deaconess Medical Center, Inc.	Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells
CA2990699A1 (en)	2015-06-29	2017-01-05	Ionis Pharmaceuticals, Inc.	Modified crispr rna and modified single crispr rna and uses thereof
US10494632B2 (en)	2015-07-10	2019-12-03	Alnylam Pharmaceuticals, Inc.	Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof
PE20180800A1 (es)	2015-07-10	2018-05-09	Ionis Pharmaceuticals Inc	Moduladores de diaciglicerol aciltransferasa 2 (dgat2)
DK3324980T3 (da)	2015-07-17	2022-02-14	Alnylam Pharmaceuticals Inc	Multimålrettede enkeltenhedskonjugater
WO2017023861A1 (en)	2015-08-03	2017-02-09	The Regents Of The University Of California	Compositions and methods for modulating abhd2 activity
WO2017035278A1 (en)	2015-08-24	2017-03-02	Halo-Bio Rnai Therapeutics, Inc.	Polynucleotide nanoparticles for the modulation of gene expression and uses thereof
HK1252479A1 (zh)	2015-08-24	2019-05-24	Roche Innovation Center Copenhagen A/S	Lna-g方法
CN108368507B (zh)	2015-09-02	2022-03-22	阿尔尼拉姆医药品有限公司	程序性细胞死亡1配体1(PD-L1)的iRNA组合物及其使用方法
CN108271360B (zh)	2015-09-14	2023-01-24	得克萨斯州大学系统董事会	亲脂阳离子树枝状聚合物及其用途
WO2017048843A1 (en)	2015-09-14	2017-03-23	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the alas1 gene
CN108366990B (zh)	2015-09-24	2021-09-03	加利福尼亚大学董事会	合成的鞘脂类分子、药物、它们的合成方法及治疗方法
HK1255699A1 (zh)	2015-09-24	2019-08-23	Ionis Pharmaceuticals, Inc.	Kras表达的调节剂
US10533175B2 (en)	2015-09-25	2020-01-14	Ionis Pharmaceuticals, Inc.	Compositions and methods for modulating Ataxin 3 expression
EP4474389A3 (de)	2015-10-08	2025-03-19	Ionis Pharmaceuticals, Inc.	Verbindungen und verfahren zur modulation der angiotensinogenexpression
WO2017062835A2 (en)	2015-10-09	2017-04-13	Sarepta Therapeutics, Inc.	Compositions and methods for treating duchenne muscular dystrophy and related disorders
AU2016334804B2 (en)	2015-10-09	2022-03-31	University Of Southampton	Modulation of gene expression and screening for deregulated protein expression
EP4089175A1 (de)	2015-10-13	2022-11-16	Duke University	Genom-engineering mit typ-i-crispr-systemen in eukaryotischen zellen
WO2017068087A1 (en)	2015-10-22	2017-04-27	Roche Innovation Center Copenhagen A/S	Oligonucleotide detection method
US11260073B2 (en)	2015-11-02	2022-03-01	Ionis Pharmaceuticals, Inc.	Compounds and methods for modulating C90RF72
EP3370708A4 (de)	2015-11-06	2019-06-26	Ionis Pharmaceuticals, Inc.	Modulation der apolipoprotein (a)-expression
SI4119569T1 (sl)	2015-11-06	2024-10-30	Ionis Pharmaceuticals, Inc.	Konjugirane protismiselne spojine za uporabo v terapiji
UA125963C2 (uk)	2015-11-12	2022-07-20	Ф. Хоффманн-Ля Рош Аг	Олігонуклеотид для індукції батьківської експресії ube3a
EP3377630A4 (de)	2015-11-16	2020-01-01	Olix Pharmaceuticals, Inc.	Behandlung von altersbedingter makuladegeneration mit auf myd88 oder tlr3 abzielenden rna-komplexen
WO2017091630A1 (en)	2015-11-23	2017-06-01	The Regents Of The University Of California	Tracking and manipulating cellular rna via nuclear delivery of crispr/cas9
WO2017095967A2 (en)	2015-11-30	2017-06-08	Duke University	Therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use
US11058709B1 (en)	2015-12-04	2021-07-13	Ionis Pharmaceuticals, Inc.	Methods of treating breast cancer
SG11201804729RA (en)	2015-12-07	2018-07-30	Genzyme Corp	Methods and compositions for treating a serpinc1-associated disorder
US11096956B2 (en)	2015-12-14	2021-08-24	Stoke Therapeutics, Inc.	Antisense oligomers and uses thereof
ES2882500T3 (es)	2015-12-14	2021-12-02	Cold Spring Harbor Laboratory	Oligómeros antisentido para el tratamiento del síndrome de Dravet
WO2017106767A1 (en)	2015-12-18	2017-06-22	The Scripps Research Institute	Production of unnatural nucleotides using a crispr/cas9 system
EP4678748A2 (de)	2015-12-21	2026-01-14	Novartis AG	Zusammensetzungen und verfahren zur verminderung der tau-expression
CA3006015A1 (en)	2015-12-31	2017-07-06	Ionis Pharmaceuticals, Inc.	Methods for reducing ataxin-2 expression
AU2017205462A1 (en)	2016-01-05	2018-06-07	Ionis Pharmaceuticals, Inc.	Methods for reducing LRRK2 expression
JP6944942B2 (ja)	2016-02-02	2021-10-06	オリックスファーマシューティカルズ，インコーポレーテッド	ＩＬ４Ｒα、ＴＲＰＡ１、またはＦ２ＲＬ１を標的とするＲＮＡ複合体を用いたアトピー性皮膚炎および喘息の治療
JP7033072B2 (ja)	2016-02-25	2022-03-09	ザブリガムアンドウィメンズホスピタルインコーポレイテッド	Ｓｍｏｃ２を標的化する線維症のための治療方法
US11136577B2 (en)	2016-03-09	2021-10-05	Ionis Pharmaceuticals, Inc.	Methods and compositions for inhibiting PMP22 expression
TWI794662B (zh)	2016-03-14	2023-03-01	瑞士商赫孚孟拉羅股份公司	用於降低pd-l1表現之寡核苷酸
EP3429690A4 (de)	2016-03-16	2019-10-23	Ionis Pharmaceuticals, Inc.	Verfahren zur modulation von keap1
WO2017161168A1 (en)	2016-03-16	2017-09-21	Ionis Pharmaceuticals, Inc.	Modulation of dyrk1b expression
ES2933435T3 (es)	2016-04-13	2023-02-08	Ionis Pharmaceuticals Inc	Métodos para reducir la expresión de C9ORF72
EP3443081A4 (de)	2016-04-13	2019-10-30	Duke University	Crispr/cas9-basierte repressoren zur in-vivo-ausschaltung von gen-targets und verfahren zur verwendung
EP3442983A1 (de)	2016-04-14	2019-02-20	H. Hoffnabb-La Roche Ag	Trityl-mono-galnac-verbindungen und deren verwendung
MY200252A (en)	2016-04-18	2023-12-16	Sarepta Therapeutics Inc	Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene
WO2017184689A1 (en)	2016-04-19	2017-10-26	Alnylam Pharmaceuticals, Inc.	High density lipoprotein binding protein (hdlbp/vigilin) irna compositions and methods of use thereof
WO2017190041A1 (en)	2016-04-29	2017-11-02	Sarepta Therapeutics, Inc.	Oligonucleotide analogues targeting human lmna
WO2017188898A1 (en)	2016-04-29	2017-11-02	Nanyang Technological University	G-quadruplex-containing antisense oligonucleotides
KR102706686B1 (ko)	2016-05-06	2024-09-19	아이오니스 파마수티컬즈, 인코포레이티드	Glp-1 수용체 리간드 모이어티 컨쥬게이트된 올리고뉴클레오티드 및 이의 용도
AU2017267634C1 (en)	2016-05-16	2022-05-26	The Board Of Regents Of The University Of Texas System	Cationic sulfonamide amino lipids and amphiphilic zwitterionic amino lipids
MX383656B (es)	2016-05-24	2025-03-14	Sarepta Therapeutics Inc	Procesos para preparar oligómeros de morfolino fosforodiamidato.
IL263044B2 (en)	2016-05-24	2024-06-01	Sarepta Therapeutics Inc	Processes for preparing phosphorodiamidate morpholino oligomers
SG10202101834QA (en)	2016-05-24	2021-04-29	Sarepta Therapeutics Inc	Processes for preparing phosphorodiamidate morpholino oligomers
US10905710B2 (en)	2016-05-24	2021-02-02	Emory University	Particles with RNA cleaving nucleobase polymers and uses for managing inflammatory disorders
US11472824B2 (en)	2016-05-24	2022-10-18	Sarepta Therapeutics, Inc.	Processes for preparing phosphorodiamidate morpholino oligomers
SG10202101830WA (en)	2016-05-24	2021-04-29	Sarepta Therapeutics Inc	Processes for preparing oligomers
WO2017214518A1 (en)	2016-06-10	2017-12-14	Alnylam Pharmaceuticals, Inc.	COMPLETMENT COMPONENT C5 iRNA COMPOSTIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
WO2017218884A1 (en)	2016-06-16	2017-12-21	Ionis Pharmaceuticals, Inc.	Combinations for the modulation of smn expression
CA3023514A1 (en)	2016-06-17	2017-12-21	Ionis Pharmaceuticals, Inc.	Modulation of gys1 expression
AU2017285350A1 (en)	2016-06-17	2018-12-20	F. Hoffmann-La Roche Ag	Nucleic acid molecules for reduction of PAPD5 or PAPD7 mRNA for treating hepatitis B infection
EP3475424A1 (de)	2016-06-22	2019-05-01	ProQR Therapeutics II B.V.	Einzelsträngige oligonukleotide zur rna-editierung
EP4163293A1 (de)	2016-06-24	2023-04-12	The Scripps Research Institute	Neuartiger nukleosid-triphosphat-transporter und verwendungen davon
AU2017290231A1 (en)	2016-06-30	2019-02-07	Sarepta Therapeutics, Inc.	Exon skipping oligomers for muscular dystrophy
EP3478839A1 (de)	2016-07-01	2019-05-08	H. Hoffnabb-La Roche Ag	Antisense-oligonukleotide zur modulierung der htra1-expression
ES2935658T3 (es)	2016-07-15	2023-03-09	Ionis Pharmaceuticals Inc	Compuestos y métodos para la modulación de SMN2
EP4275747A3 (de)	2016-07-19	2024-01-24	Duke University	Therapeutische anwendungen von cpf1-basierter genomeditierung
WO2018017814A1 (en)	2016-07-20	2018-01-25	President And Fellows Of Harvard College	Peptidoglycan glycosyltransferase inhibitors of sed proteins for treating bacterial infections
CA3035293A1 (en)	2016-09-01	2018-03-08	Proqr Therapeutics Ii B.V.	Chemically modified single-stranded rna-editing oligonucleotides
US11202818B2 (en)	2016-09-14	2021-12-21	President And Fellows Of Harvard College	Methods and compositions for modulating erythropoiesis
TWI769177B (zh)	2016-09-14	2022-07-01	美商艾洛斯生物製藥公司	經修飾之寡核苷酸及使用方法
ES2963428T3 (es)	2016-09-29	2024-03-27	Biogen Ma Inc	Compuestos y métodos para reducir la expresión de Tau
KR20190065341A (ko)	2016-10-06	2019-06-11	아이오니스 파마수티컬즈, 인코포레이티드	올리고머 화합물들의 접합 방법
CA3037046A1 (en)	2016-10-31	2018-05-03	University Of Massachusetts	Targeting microrna-101-3p in cancer therapy
JOP20190104A1 (ar)	2016-11-10	2019-05-07	Ionis Pharmaceuticals Inc	مركبات وطرق لتقليل التعبير عن atxn3
WO2018087200A1 (en)	2016-11-11	2018-05-17	Roche Innovation Center Copenhagen A/S	Therapeutic oligonucleotides capture and detection
TW202313978A (zh)	2016-11-23	2023-04-01	美商阿尼拉製藥公司	絲胺酸蛋白酶抑制因子Ａ１ｉＲＮＡ組成物及其使用方法
US11033570B2 (en)	2016-12-02	2021-06-15	Cold Spring Harbor Laboratory	Modulation of Lnc05 expression
WO2018112033A1 (en)	2016-12-13	2018-06-21	President And Fellows Of Harvard College	Methods and compositions for targeting tumor-infiltrating tregs
AU2017376950B2 (en)	2016-12-16	2024-02-22	Alnylam Pharmaceuticals, Inc.	Methods for treating or preventing TTR-associated diseases using transthyretin (TTR) iRNA compositions
CN117298290A (zh)	2016-12-19	2023-12-29	萨勒普塔医疗公司	用于肌肉萎缩症的外显子跳跃寡聚体缀合物
EP3554552B1 (de)	2016-12-19	2022-08-17	Sarepta Therapeutics, Inc.	Exon-skipping-oligomerkonjugate für muskeldystrophie
LT3554553T (lt)	2016-12-19	2022-08-25	Sarepta Therapeutics, Inc.	Egzoną šalinantys oligomero konjugatai nuo raumenų distrofojos
WO2018130581A1 (en)	2017-01-13	2018-07-19	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides for modulating rela expression
WO2018130585A1 (en)	2017-01-13	2018-07-19	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides for modulating relb expression
EP3568480A1 (de)	2017-01-13	2019-11-20	Roche Innovation Center Copenhagen A/S	Antisense-oligonukleotide zur modulierung der nfkb2-expression
WO2018130583A1 (en)	2017-01-13	2018-07-19	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides for modulating nfkb1 expression
US20190338286A1 (en)	2017-01-13	2019-11-07	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides for modulating rel expression
EP3571300A1 (de)	2017-01-19	2019-11-27	ProQR Therapeutics II B.V.	Oligonukleotidkomplexe zur verwendung bei der rna-editierung
US11180756B2 (en)	2017-03-09	2021-11-23	Ionis Pharmaceuticals	Morpholino modified oligomeric compounds
JOP20190215A1 (ar)	2017-03-24	2019-09-19	Ionis Pharmaceuticals Inc	مُعدّلات التعبير الوراثي عن pcsk9
WO2018191603A1 (en)	2017-04-14	2018-10-18	University Of Massachusetts	Targeting cell tropism receptors to inhibit cytomegalovirus infection
SG11201909572QA (en)	2017-04-18	2019-11-28	Alnylam Pharmaceuticals Inc	Methods for the treatment of subjects having a hepatitis b virus (hbv) infection
CN110536694A (zh)	2017-04-20	2019-12-03	Atyr 医药公司	用于治疗肺部炎症的组合物和方法
CA3062595A1 (en)	2017-05-10	2018-11-15	The Regents Of The University Of California	Directed editing of cellular rna via nuclear delivery of crispr/cas9
US20190055564A1 (en)	2017-06-01	2019-02-21	F. Hoffmann-La Roche Ag	Antisense oligonucleotides for modulating htra1 expression
JP2020530442A (ja)	2017-07-10	2020-10-22	ジェンザイム・コーポレーション	血友病を有する対象の出血事象を処置するための方法および組成物
SG11202000167SA (en)	2017-07-11	2020-02-27	Synthorx Inc	Incorporation of unnatural nucleotides and methods thereof
MA49716A (fr)	2017-07-11	2021-04-07	Scripps Research Inst	Incorporation de nucléotides non naturels et procédés d'utilisationin vivo
KR20250145137A (ko)	2017-08-03	2025-10-13	신톡스, 인크.	자가면역 질환의 치료를 위한 사이토카인 접합체
WO2019030313A2 (en)	2017-08-11	2019-02-14	Roche Innovation Center Copenhagen A/S	OLIGONUCLEOTIDES FOR MODULATION OF UBE3C EXPRESSION
AU2018318231A1 (en)	2017-08-18	2020-02-13	Ionis Pharmaceuticals, Inc.	Modulation of the notch signaling pathway for treatment of respiratory disorders
WO2019038228A1 (en)	2017-08-22	2019-02-28	Roche Innovation Center Copenhagen A/S	OLIGONUCLEOTIDES FOR MODULATION OF TOM1 EXPRESSION
SI3673080T1 (sl)	2017-08-25	2024-03-29	Stoke Therapeutics, Inc.	Protismiselni oligomeri za zdravljenje bolezenskih stanj in bolezni
US10517889B2 (en)	2017-09-08	2019-12-31	Ionis Pharmaceuticals, Inc.	Modulators of SMAD7 expression
SG11202002149XA (en)	2017-09-14	2020-04-29	Janssen Biopharma Inc	Galnac derivatives
EA201991450A1 (ru)	2017-09-22	2019-12-30	Сарепта Терапьютикс, Инк.	Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
JP2020536057A (ja)	2017-09-28	2020-12-10	サレプタセラピューティクス，インコーポレイテッド	筋ジストロフィーを処置するための併用療法
EP3687577A1 (de)	2017-09-28	2020-08-05	Sarepta Therapeutics, Inc.	Kombinationstherapien zur behandlung von muskeldystrophie
JP2020536060A (ja)	2017-09-28	2020-12-10	サレプタセラピューティクス，インコーポレイテッド	筋ジストロフィーを処置するための併用療法
CN111226114A (zh)	2017-10-13	2020-06-02	罗氏创新中心哥本哈根有限公司	用部分立体限定的寡核苷酸子文库鉴定反义寡核苷酸改进的立体限定硫代磷酸酯寡核苷酸变体的方法
CN111511914B (zh)	2017-10-16	2023-11-17	豪夫迈·罗氏有限公司	减少PAPD5和PAPD7 mRNA的核酸分子用于治疗乙型肝炎感染
US11261445B2 (en)	2017-10-17	2022-03-01	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Combination treatment for cystic fibrosis
WO2019079637A2 (en)	2017-10-18	2019-04-25	Sarepta Therapeutics, Inc.	ANTISENSE OLIGOMERIC COMPOUNDS
US11866701B2 (en)	2017-11-01	2024-01-09	Alnylam Pharmaceuticals, Inc.	Complement component C3 iRNA compositions and methods of use thereof
TWI809004B (zh)	2017-11-09	2023-07-21	美商Ionis製藥公司	用於降低snca表現之化合物及方法
US20200385719A1 (en)	2017-11-16	2020-12-10	Alnylam Pharmaceuticals, Inc.	Kisspeptin 1 (kiss1) irna compositions and methods of use thereof
EP3714054A1 (de)	2017-11-20	2020-09-30	Alnylam Pharmaceuticals, Inc.	Serum-amyloid p-komponente (apcs) irna zusammensetzungen und verfahren zu deren verwendung
US20200385714A1 (en)	2017-12-11	2020-12-10	Roche Innovation Center Copenhagen A/S	Oligonucleotides for modulating fndc3b expression
WO2019115417A2 (en)	2017-12-12	2019-06-20	Roche Innovation Center Copenhagen A/S	Oligonucleotides for modulating rb1 expression
EP3724206B1 (de)	2017-12-14	2023-06-28	Ionis Pharmaceuticals, Inc.	Konjugierte antisense-verbindungen und deren verwendung
WO2019126097A1 (en)	2017-12-18	2019-06-27	Alnylam Pharmaceuticals, Inc.	High mobility group box-1 (hmgb1) irna compositions and methods of use thereof
WO2019126641A2 (en)	2017-12-21	2019-06-27	Ionis Pharmaceuticals, Inc.	Modulation of frataxin expression
JP2021507253A (ja)	2017-12-21	2021-02-22	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	Ｈｔｒａ１ｒｎａアンタゴニストについてのコンパニオン診断
TW201929870A (zh)	2017-12-22	2019-08-01	丹麥商羅氏創新中心哥本哈根有限公司	包含二硫代磷酸酯核苷間連結之寡核苷酸
CA3084170A1 (en)	2017-12-22	2019-06-27	Roche Innovation Center Copenhagen A/S	Gapmer oligonucleotides comprising a phosphorodithioate internucleoside linkage
JP2021508327A (ja) *	2017-12-22	2021-03-04	ロシュイノベーションセンターコペンハーゲンエーエス	新規のチオホスホラミダイト
IL275694B2 (en)	2017-12-29	2025-08-01	Scripps Research Inst	Unnatural base pair compositions and methods of use
WO2019137883A1 (en)	2018-01-10	2019-07-18	Roche Innovation Center Copenhagen A/S	Oligonucleotides for modulating pias4 expression
US12241065B2 (en)	2018-01-12	2025-03-04	Bristol-Myers Squibb Company	Antisense oligonucleotides targeting alpha-synuclein and uses thereof
US20210095275A1 (en)	2018-01-12	2021-04-01	Roche Innovation Center Copenhagen A/S	Oligonucleotides for modulating gsk3b expression
CN120310791A (zh)	2018-01-12	2025-07-15	百时美施贵宝公司	靶向α-突触核蛋白的反义寡核苷酸及其用途
MA51634A (fr)	2018-01-12	2020-11-18	Roche Innovation Ct Copenhagen As	Oligonucléotides antisens d'alpha-synucléine et leurs utilisations
US20200392510A1 (en)	2018-01-15	2020-12-17	Ionis Pharmaceuticals, Inc.	Modulators of dnm2 expression
EP3740574A1 (de)	2018-01-17	2020-11-25	Roche Innovation Center Copenhagen A/S	Oligonukleotide zur modulierung der erc1-expression
WO2019141723A1 (en)	2018-01-18	2019-07-25	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting srebp1
US12509492B2 (en)	2018-01-19	2025-12-30	Duke University	Genome engineering with CRISPR-Cas systems in eukaryotes
WO2019145386A1 (en)	2018-01-26	2019-08-01	Roche Innovation Center Copenhagen A/S	Oligonucleotides for modulating csnk1d expression
RU2020125769A (ru)	2018-02-09	2022-03-10	Дженентек, Инк.	Олигонуклеотиды для модуляции экспрессии tmem106b
CA3090901A1 (en)	2018-02-12	2019-08-15	Ionis Pharmaceuticals, Inc.	Modified compounds and uses thereof
CA3091789A1 (en)	2018-02-21	2019-08-29	Bristol-Myers Squibb Company	Camk2d antisense oligonucleotides and uses thereof
WO2019165453A1 (en)	2018-02-26	2019-08-29	Synthorx, Inc.	Il-15 conjugates and uses thereof
US11732260B2 (en)	2018-03-02	2023-08-22	Ionis Pharmaceuticals, Inc.	Compounds and methods for the modulation of amyloid-β precursor protein
TWI840345B (zh)	2018-03-02	2024-05-01	美商Ionis製藥公司	Irf4表現之調節劑
BR112020018365A2 (pt)	2018-03-13	2020-12-29	Janssen Pharmaceutica Nv	Oligonucleotídeos modificados e métodos para uso em tauopatias
EP3768694A4 (de)	2018-03-22	2021-12-29	Ionis Pharmaceuticals, Inc.	Verfahren zur modulierung der fmr1-expression
EP3775208A1 (de)	2018-04-05	2021-02-17	F. Hoffmann-La Roche AG	Verwendung von fubp1-inhibitoren zur behandlung von hepatitis-b-virus-infektionen
CA3094020A1 (en)	2018-04-11	2019-10-17	Ionis Pharmaceuticals, Inc.	Modulators of ezh2 expression
US12263205B2 (en)	2018-04-30	2025-04-01	The Children's Hospital Of Philadelphia	Methods of improving anemias by combining agents
WO2019213525A1 (en)	2018-05-04	2019-11-07	Stoke Therapeutics, Inc.	Methods and compositions for treatment of cholesteryl ester storage disease
EP3790970A1 (de)	2018-05-07	2021-03-17	Alnylam Pharmaceuticals Inc.	Extrahepatische verabreichung
JP2021522816A (ja)	2018-05-07	2021-09-02	ロシュイノベーションセンターコペンハーゲンエーエス	オリゴヌクレオチド治療のための超並列的探索方法
WO2019215175A1 (en)	2018-05-08	2019-11-14	Roche Innovation Center Copenhagen A/S	Oligonucleotides for modulating myh7 expression
JP7438135B2 (ja)	2018-05-09	2024-02-26	アイオーニスファーマシューティカルズ，インコーポレーテッド	Ｆｘｉの発現を低下させるための化合物及び方法
SG11202010215TA (en)	2018-05-09	2020-11-27	Ionis Pharmaceuticals Inc	Compounds and methods for reducing atxn3 expression
CA3099963A1 (en)	2018-05-11	2019-11-14	University Of Massachusetts	Methods for improving leptin sensitivity for the treatment of obesity and diabetes
TWI851574B (zh)	2018-05-14	2024-08-11	美商阿尼拉製藥公司	血管收縮素原（ＡＧＴ）ｉＲＮＡ組成物及其使用方法
GB201808146D0 (en)	2018-05-18	2018-07-11	Proqr Therapeutics Ii Bv	Stereospecific Linkages in RNA Editing Oligonucleotides
JP2021524450A (ja)	2018-05-18	2021-09-13	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	マイクロｒｎａ関連疾患の処置のための薬学的組成物
WO2019224172A1 (en)	2018-05-25	2019-11-28	Roche Innovation Center Copenhagen A/S	Novel process for making allofuranose from glucofuranose
US10758629B2 (en)	2018-05-29	2020-09-01	Sarepta Therapeutics, Inc.	Exon skipping oligomer conjugates for muscular dystrophy
CN112912500A (zh)	2018-06-05	2021-06-04	豪夫迈·罗氏有限公司	用于调节atxn2表达的寡核苷酸
EP3806868A4 (de)	2018-06-13	2022-06-22	Sarepta Therapeutics, Inc.	Exon-skipping-oligomere für muskeldystrophie
US11833168B2 (en)	2018-06-14	2023-12-05	Ionis Pharmaceuticals, Inc.	Compounds and methods for increasing STMN2 expression
WO2019246450A1 (en)	2018-06-20	2019-12-26	Yale University	Rig-i agonists and treatments using same
JP7595464B2 (ja)	2018-06-21	2024-12-06	エフ．ホフマン－ラロシュアーゲー	全ｌｎａオリゴヌクレオチドのハイブリダイズ
TWI833770B (zh)	2018-06-27	2024-03-01	美商Ionis製藥公司	用於減少 lrrk2 表現之化合物及方法
WO2020007700A1 (en)	2018-07-02	2020-01-09	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting spi1
WO2020007702A1 (en)	2018-07-02	2020-01-09	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting bcl2l11
WO2020007772A1 (en)	2018-07-02	2020-01-09	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting gbp-1
WO2020007892A1 (en)	2018-07-03	2020-01-09	F. Hoffmann-La Roche Ag	Oligonucleotides for modulating tau expression
WO2020007826A1 (en)	2018-07-05	2020-01-09	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting mbtps1
WO2020007889A1 (en)	2018-07-05	2020-01-09	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting stat1
WO2020011653A1 (en)	2018-07-09	2020-01-16	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting kynu
WO2020011743A1 (en)	2018-07-09	2020-01-16	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting mafb
WO2020011744A2 (en)	2018-07-11	2020-01-16	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting cers5
WO2020011745A2 (en)	2018-07-11	2020-01-16	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting cers6
WO2020011869A2 (en)	2018-07-11	2020-01-16	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting tlr2
JP7616987B2 (ja)	2018-07-13	2025-01-17	エフ．ホフマン－ラロシュアーゲー	Ｒｔｅｌ１発現の調節用のオリゴヌクレオチド
EP3823725A4 (de)	2018-07-17	2023-05-10	Aronora, Inc.	Verfahren zur sicheren reduzierung von thrombopoietin
CA3106986A1 (en)	2018-07-25	2020-01-30	Ionis Pharmaceuticals, Inc.	Compounds and methods for reducing atxn2 expression
TW202020153A (zh)	2018-07-27	2020-06-01	美商薩羅塔治療公司	用於肌肉萎縮症之外顯子跳躍寡聚物
JP7470097B2 (ja)	2018-07-31	2024-04-17	ロシュイノベーションセンターコペンハーゲンエーエス	ホスホロトリチオアートヌクレオシド間結合を含むオリゴヌクレオチド
KR20210041537A (ko)	2018-07-31	2021-04-15	로슈 이노베이션 센터 코펜하겐 에이/에스	포스포로트리티오에이트 뉴클레오사이드간 연결을 포함하는 올리고뉴클레오타이드
MA70658B1 (fr)	2018-08-13	2026-04-30	Alnylam Pharmaceuticals, Inc.	Compositions d'agent d'arndb du virus de l'hépatite b (vhb) et leurs méthodes d'utilisation
US11987792B2 (en)	2018-08-16	2024-05-21	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the LECT2 gene
CA3110211A1 (en)	2018-08-20	2020-02-27	Rogcon, Inc.	Antisense oligonucleotides targeting scn2a for the treatment of scn1a encephalopathies
WO2020038971A1 (en)	2018-08-23	2020-02-27	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting vcan
WO2020038968A1 (en)	2018-08-23	2020-02-27	Roche Innovation Center Copenhagen A/S	Microrna-134 biomarker
WO2020038973A1 (en)	2018-08-23	2020-02-27	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting sptlc1
WO2020038976A1 (en)	2018-08-23	2020-02-27	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting usp8
EP3844274A1 (de)	2018-08-28	2021-07-07	Roche Innovation Center Copenhagen A/S	Neoantigen-engineering unter verwendung von spleissmodulierenden verbindungen
US12281308B2 (en)	2018-08-29	2025-04-22	University Of Massachusetts	Inhibition of protein kinases to treat Friedreich ataxia
EP3620519A1 (de)	2018-09-04	2020-03-11	F. Hoffmann-La Roche AG	Verwendung von isolierten extrazellulären vesikeln aus milch zur oralen verabreichung von oligonukleotiden
US11273137B2 (en)	2018-09-04	2022-03-15	Board Of Trustees Of Michigan State University	Methods and compositions to prevent and treat disorders associated with mutations in the ODC1 gene
EP3846824B1 (de)	2018-09-07	2025-06-18	The General Hospital Corporation	Zusammensetzungen und verfahren zur immuncheckpoint-inhibition
EP3620520A1 (de)	2018-09-10	2020-03-11	Universidad del Pais Vasco	Neuartiges target zur behandlung einer stoffwechselerkrankung in einem individuum
WO2020060986A1 (en)	2018-09-18	2020-03-26	Alnylam Pharmaceuticals, Inc.	Ketohexokinase (khk) irna compositions and methods of use thereof
TWI869213B (zh)	2018-09-19	2025-01-01	美商Ionis製藥公司	Pnpla3表現之調節劑
JP7470107B2 (ja)	2018-09-28	2024-04-17	アルナイラムファーマシューティカルズ，インコーポレイテッド	トランスサイレチン（ＴＴＲ）ｉＲＮＡ組成物及びＴＴＲ関連眼疾患を治療又は予防するためのその使用方法
US10913951B2 (en)	2018-10-31	2021-02-09	University of Pittsburgh—of the Commonwealth System of Higher Education	Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
WO2020089260A1 (en)	2018-11-01	2020-05-07	F. Hoffmann-La Roche Ag	Antisense oligonucleotides targeting tia1
BR112021005401A2 (pt)	2018-11-08	2021-06-29	Synthorx, Inc.	conjugados de interleucina 10 e usos dos mesmos
TW202028222A (zh)	2018-11-14	2020-08-01	美商Ionis製藥公司	Foxp3表現之調節劑
EA202191342A1 (ru)	2018-11-15	2021-08-10	Айонис Фармасьютикалз, Инк.	Модуляторы экспрессии irf5
US12281305B2 (en)	2018-11-21	2025-04-22	Ionis Pharmaceuticals, Inc.	Compounds and methods for reducing prion expression
CN113166185A (zh)	2018-11-22	2021-07-23	罗氏创新中心哥本哈根有限公司	作为立体限定的寡核苷酸合成中的活化剂的吡啶鎓盐
WO2020109343A1 (en)	2018-11-29	2020-06-04	F. Hoffmann-La Roche Ag	Combination therapy for treatment of macular degeneration
WO2020109344A1 (en)	2018-11-29	2020-06-04	F. Hoffmann-La Roche Ag	Occular administration device for antisense oligonucleotides
WO2020117706A1 (en)	2018-12-03	2020-06-11	Triplet Therapeutics, Inc.	Methods for the treatment of trinucleotide repeat expansion disorders associated with mlh3 activity
IL321667A (en)	2018-12-13	2025-08-01	Sarepta Therapeutics Inc	Exon skipping oligomer conjugates for muscular dystrophy
JP7562424B2 (ja)	2018-12-17	2024-10-07	イルミナケンブリッジリミテッド	シーケンシング用プライマーオリゴヌクレオチド
LT4285929T (lt)	2018-12-20	2026-01-12	Humabs Biomed Sa	Kompleksinė hbv terapija
CN113631709A (zh)	2018-12-20	2021-11-09	普拉克西斯精密药物股份有限公司	用于治疗kcnt1相关病症的组合物和方法
EP3898975A2 (de)	2018-12-21	2021-10-27	Boehringer Ingelheim International GmbH	Gegen card9 gerichtete antisense-oligonukleotide
US20220273691A1 (en)	2018-12-21	2022-09-01	Ionis Pharmaceuticals, Inc.	Modulators of hsd17b13 expression
CN113557023A (zh)	2019-01-16	2021-10-26	建新公司	Serpinc1 iRNA组合物及其使用方法
EP3914232A1 (de)	2019-01-25	2021-12-01	F. Hoffmann-La Roche AG	Lipidvesikel zur oralen wirkstoffverabreichung
MX2021008918A (es)	2019-01-31	2021-08-24	Ionis Pharmaceuticals Inc	Moduladores de expresion yap1.
US20200246467A1 (en)	2019-02-06	2020-08-06	Synthorx, Inc.	Il-2 conjugates and methods of use thereof
CA3129646A1 (en)	2019-02-20	2020-08-27	Roche Innovation Center Copenhagen A/S	Novel phosphoramidites
CA3130431A1 (en)	2019-02-20	2020-08-27	Roche Innovation Center Copenhagen A/S	Phosphonoacetate gapmer oligonucleotides
JP7503072B2 (ja)	2019-02-26	2024-06-19	ロシュイノベーションセンターコペンハーゲンエーエス	オリゴヌクレオチドの製剤化方法
WO2020176771A1 (en)	2019-02-27	2020-09-03	Ionis Pharmaceuticals, Inc.	Modulators of malat1 expression
KR20210134003A (ko)	2019-02-27	2021-11-08	스톡 테라퓨틱스, 인크.	병태 및 질환의 치료를 위한 안티센스 올리고머
US12215382B2 (en)	2019-03-01	2025-02-04	The General Hospital Corporation	Liver protective MARC variants and uses thereof
EP3934695A1 (de)	2019-03-05	2022-01-12	F. Hoffmann-La Roche AG	Intrazelluläres molekül-targeting
JP2022523779A (ja)	2019-03-12	2022-04-26	プレジデントアンドフェローズオブハーバードカレッジ	癌を処置するための方法および組成物
WO2020191177A1 (en)	2019-03-21	2020-09-24	Sudhir Agrawal	Antisense oligonucleotides for allele specificity
CA3133314A1 (en)	2019-03-21	2020-09-24	Codiak Biosciences, Inc.	Extracellular vesicle conjugates and uses thereof
CA3135180A1 (en)	2019-03-29	2020-10-08	Ionis Pharmaceuticals, Inc.	Compounds and methods for modulating ube3a-ats
WO2020206115A2 (en)	2019-04-03	2020-10-08	Bristol-Myers Squibb Company	Angptl2 antisense oligonucleotides and uses thereof
US11286485B2 (en)	2019-04-04	2022-03-29	Hoffmann-La Roche Inc.	Oligonucleotides for modulating ATXN2 expression
EP3947677A1 (de)	2019-04-04	2022-02-09	F. Hoffmann-La Roche AG	Oligonukleotide zur modulierung der atxn2-expression
CN113661168A (zh)	2019-04-16	2021-11-16	罗氏创新中心哥本哈根有限公司	用于制备核苷酸p(v)单体的新方法
US20220193246A1 (en)	2019-04-18	2022-06-23	Sarepta Therapeutics, Inc.	Compositions for treating muscular dystrophy
WO2020221705A1 (en)	2019-04-30	2020-11-05	Roche Innovation Center Copenhagen A/S	Novel process for preparing rhenium chelated mag3 oligonucleotides
AU2020268798A1 (en)	2019-05-03	2021-11-04	Dicerna Pharmaceuticals, Inc.	Double-stranded nucleic acid inhibitor molecules with shortened sense strands
TWI902693B (zh)	2019-05-13	2025-11-01	美商維爾生物科技公司	用於治療ｂ型肝炎病毒（ｈｂｖ）感染之組成物及方法
US20220211743A1 (en)	2019-05-17	2022-07-07	Alnylam Pharmaceuticals, Inc.	Oral delivery of oligonucleotides
SI3976791T1 (sl)	2019-05-28	2025-06-30	Ionis Pharmaceuticals, Inc.	Spojine in postopki za zmanjševanje izražanja fus
CN113950529A (zh)	2019-06-06	2022-01-18	豪夫迈·罗氏有限公司	靶向atxn3的反义寡核苷酸
WO2020245377A1 (en)	2019-06-07	2020-12-10	F. Hoffmann-La Roche Ag	Hybridizing all-lna oligonucleotides
WO2020252257A1 (en)	2019-06-12	2020-12-17	President And Fellows Of Harvard College	Methods and compositions for modulation of an interspecies gut bacterial pathway for levodopa metabolism
BR112021025130A2 (pt)	2019-06-14	2022-03-15	Scripps Research Inst	Reagentes e métodos para replicação, transcrição e tradução em organismos semissintéticos
EP3997225A1 (de)	2019-07-10	2022-05-18	INSERM (Institut National de la Santé et de la Recherche Médicale)	Verfahren zur behandlung von epilepsie
ES3048358T3 (en)	2019-07-26	2025-12-10	Ionis Pharmaceuticals Inc	Compounds and methods for modulating gfap
EP4007812A1 (de)	2019-08-01	2022-06-08	Alnylam Pharmaceuticals, Inc.	Irna-zusammensetzungen der serpinfamilie f element 2 (serpinf2) und verfahren zu deren verwendung
EP4007811A2 (de)	2019-08-01	2022-06-08	Alnylam Pharmaceuticals, Inc.	Carboxypeptidase-b2(cpb2)-irna-zusammensetzungen und verfahren zur verwendung davon
WO2021030522A1 (en)	2019-08-13	2021-02-18	Alnylam Pharmaceuticals, Inc.	SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
WO2021030773A1 (en)	2019-08-14	2021-02-18	Codiak Biosciences, Inc.	Extracellular vesicle-nlrp3 antagonist
WO2021030769A1 (en)	2019-08-14	2021-02-18	Codiak Biosciences, Inc.	Extracellular vesicles with nras antisense oligonucleotides
CN114641570A (zh)	2019-08-14	2022-06-17	科迪亚克生物科学公司	具有靶向kras的反义寡核苷酸的细胞外囊泡
BR112022002690A2 (pt)	2019-08-14	2022-08-23	Codiak Biosciences Inc	Construtos de vesícula-aso extracelular tendo como alvo cebp/beta
JP2022544289A (ja)	2019-08-14	2022-10-17	コディアックバイオサイエンシーズ，インコーポレイテッド	Ｓｔａｔ６を標的とする細胞外小胞－ａｓｏ構築物
KR20220078565A (ko)	2019-08-14	2022-06-10	코디악 바이오사이언시즈, 인크.	분자에 연결된 세포외 소포 및 이의 용도
KR20220062517A (ko)	2019-08-15	2022-05-17	아이오니스 파마수티컬즈, 인코포레이티드	결합 변형된 올리고머 화합물 및 이의 용도
TW202543680A (zh)	2019-08-15	2025-11-16	美商欣爍克斯公司	使用il-2接合物之免疫腫瘤學組合療法
PH12022500004A1 (en)	2019-08-23	2023-04-03	Synthorx Inc	Il-15 conjugates and uses thereof
US20220290152A1 (en)	2019-09-03	2022-09-15	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the lect2 gene
MX2022002740A (es)	2019-09-10	2022-03-25	Synthorx Inc	Conjugados de il-2 y metodos de uso para tratar enfermedades autoinmunes.
US12616712B2 (en)	2019-09-25	2026-05-05	Lonza Sales Ag	Sting agonist comprising exosomes for treating neuroimmunological disorders
WO2021067747A1 (en)	2019-10-04	2021-04-08	Alnylam Pharmaceuticals, Inc.	Compositions and methods for silencing ugt1a1 gene expression
JP7757277B2 (ja)	2019-10-14	2025-10-21	アストラゼネカ・アクチエボラーグ	Ｐｎｐｌａ３発現のモジュレーター
WO2021074657A1 (en)	2019-10-17	2021-04-22	INSERM (Institut National de la Santé et de la Recherche Médicale)	Combination treatment for cystic fibrosis
WO2021076828A1 (en)	2019-10-18	2021-04-22	Alnylam Pharmaceuticals, Inc.	Solute carrier family member irna compositions and methods of use thereof
BR112022007540A2 (pt)	2019-10-22	2022-07-12	Alnylam Pharmaceuticals Inc	Composições de irna de componente complementar c3 e métodos de uso das mesmas
CN114728018B (zh)	2019-11-01	2024-07-19	阿尔尼拉姆医药品有限公司	亨廷顿(HTT)iRNA药剂组合物及其使用方法
WO2021087325A1 (en)	2019-11-01	2021-05-06	Alnylam Pharmaceuticals, Inc.	Compositions and methods for silencing dnajb1-prkaca fusion gene expression
AU2020380275A1 (en)	2019-11-04	2022-04-14	Synthorx, Inc.	Interleukin 10 conjugates and uses thereof
AU2020378414A1 (en)	2019-11-06	2022-05-26	Alnylam Pharmaceuticals, Inc.	Extrahepatic delivery
EP4055165A1 (de)	2019-11-06	2022-09-14	Alnylam Pharmaceuticals, Inc.	Transthyretin (ttr)-irna-zusammensetzungen und verfahren zur verwendung davon für die behandlung oder prävention ttr-assoziierter augenerkrankungen
TW202526019A (zh)	2019-11-13	2025-07-01	美商阿尼拉製藥公司	用於治療血管收縮素原相關病症之方法及組成物
WO2021099394A1 (en)	2019-11-19	2021-05-27	INSERM (Institut National de la Santé et de la Recherche Médicale)	Antisense oligonucleotides and their use for the treatment of cancer
EP4061945A1 (de)	2019-11-22	2022-09-28	Alnylam Pharmaceuticals, Inc.	Ataxin3 (atxn3)-rnai-wirkstoffzusammensetzungen und verfahren zu deren verwendung
TWI897902B (zh)	2019-12-13	2025-09-21	美商阿尼拉製藥公司	人類染色體9開讀框72 (C9ORF72) iRNA劑組成物及其使用方法
WO2021126734A1 (en)	2019-12-16	2021-06-24	Alnylam Pharmaceuticals, Inc.	Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
CA3164781A1 (en) *	2019-12-18	2021-06-24	F. Hoffmann-La Roche Ag	Methods of sequencing by synthesis using a consecutive labeling scheme
EP4077671A1 (de)	2019-12-19	2022-10-26	F. Hoffmann-La Roche AG	Verwendung von saraf-inhibitoren zum behandeln von hepatitis-b-virus-infektionen
EP4706689A2 (de)	2019-12-19	2026-03-11	Entrada Therapeutics, Inc.	Zusammensetzungen zur verabreichung von antisense-verbindungen
WO2021122921A1 (en)	2019-12-19	2021-06-24	F. Hoffmann-La Roche Ag	Use of cops3 inhibitors for treating hepatitis b virus infection
WO2021122869A1 (en)	2019-12-19	2021-06-24	F. Hoffmann-La Roche Ag	Use of scamp3 inhibitors for treating hepatitis b virus infection
CN114829601A (zh)	2019-12-19	2022-07-29	豪夫迈·罗氏有限公司	Sbds抑制剂用于治疗乙型肝炎病毒感染的用途
WO2021122735A1 (en)	2019-12-19	2021-06-24	F. Hoffmann-La Roche Ag	Use of sept9 inhibitors for treating hepatitis b virus infection
TW202136510A (zh)	2019-12-20	2021-10-01	瑞士商赫孚孟拉羅股份公司	用於抑制ｓｃｎ９ａ表現之增強型寡核苷酸
CN114828852A (zh)	2019-12-24	2022-07-29	豪夫迈·罗氏有限公司	用于治疗hbv的靶向hbv的抗病毒药剂和/或免疫调节剂的药物组合
AU2020410993A1 (en)	2019-12-24	2022-06-16	F. Hoffmann-La Roche Ag	Pharmaceutical combination of a therapeutic oligonucleotide targeting hbv and a tlr7 agonist for treatment of hbv
WO2021154941A1 (en)	2020-01-31	2021-08-05	Alnylam Pharmaceuticals, Inc.	Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
WO2021158810A1 (en)	2020-02-05	2021-08-12	Bristol-Myers Squibb Company	Oligonucleotides for splice modulation of camk2d
MX2022009763A (es)	2020-02-10	2022-09-09	Alnylam Pharmaceuticals Inc	Composiciones y metodos para silenciar la expresion del factor de crecimiento endotelial vascular a (vegf-a).
WO2021167841A1 (en)	2020-02-18	2021-08-26	Alnylam Pharmaceuticals, Inc.	Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
TWI794742B (zh)	2020-02-18	2023-03-01	美商基利科學股份有限公司	抗病毒化合物
TWI874791B (zh)	2020-02-18	2025-03-01	美商基利科學股份有限公司	抗病毒化合物
AU2021224588B2 (en)	2020-02-18	2024-07-18	Gilead Sciences, Inc.	Antiviral compounds
CN115176010A (zh)	2020-02-28	2022-10-11	豪夫迈·罗氏有限公司	用于调节cd73外显子7剪接的寡核苷酸
PH12022552258A1 (en)	2020-02-28	2023-11-20	Ionis Pharmaceuticals Inc	Compounds and methods for modulating smn2
CA3167369A1 (en)	2020-03-04	2021-09-10	Tara YOUNG	Methods and compositions for sensitization of tumor cells to immune therapy
EP4114947A1 (de)	2020-03-05	2023-01-11	Alnylam Pharmaceuticals, Inc.	Komplementkomponenten-c3-irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung oder prävention von mit komplementkomponenten-c3-assoziierten erkrankungen
WO2021178736A1 (en)	2020-03-06	2021-09-10	Alnylam Pharmaceuticals, Inc.	KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
JP7802676B2 (ja)	2020-03-06	2026-01-20	アルナイラムファーマシューティカルズ，インコーポレイテッド	トランスサイレチン（ｔｔｒ）の発現を阻害するための組成物および方法
WO2021184020A1 (en)	2020-03-13	2021-09-16	Codiak Biosciences, Inc.	Methods of treating neuroinflammation
WO2021184021A1 (en)	2020-03-13	2021-09-16	Codiak Biosciences, Inc.	Extracellular vesicle-aso constructs targeting pmp22
EP4121534A1 (de)	2020-03-18	2023-01-25	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur behandlung von patienten mit einer heterozygoten alaninglyoxylat-aminotransferase-genvariante (agxt)
WO2021195307A1 (en)	2020-03-26	2021-09-30	Alnylam Pharmaceuticals, Inc.	Coronavirus irna compositions and methods of use thereof
EP4127171A2 (de)	2020-03-30	2023-02-08	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur ausschaltung der dnajc15-genexpression
CN115843299A (zh)	2020-03-31	2023-03-24	詹森生物制药有限公司	寡核苷酸的合成和相关化合物
US12534731B2 (en)	2020-04-01	2026-01-27	Alnylam Pharmaceuticals, Inc.	Alpha-2A adrenergic receptor (ADRA2A) iRNA agent compositions and methods of use thereof
CA3179411A1 (en)	2020-04-06	2021-10-14	Alnylam Pharmaceuticals, Inc.	Compositions and methods for silencing myoc expression
WO2021206917A1 (en)	2020-04-07	2021-10-14	Alnylam Pharmaceuticals, Inc.	ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
IL297130A (en)	2020-04-07	2022-12-01	Alnylam Pharmaceuticals Inc	Compositions and methods for silencing scn9a expression
WO2021206922A1 (en)	2020-04-07	2021-10-14	Alnylam Pharmaceuticals, Inc.	Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof
CA3176196A1 (en)	2020-04-21	2021-10-28	Flagship Pioneering, Inc.	Bifunctional molecules and methods of using thereof
WO2021222065A1 (en)	2020-04-27	2021-11-04	Alnylam Pharmaceuticals, Inc.	Apolipoprotein e (apoe) irna agent compositions and methods of use thereof
EP4142738A1 (de)	2020-04-30	2023-03-08	Alnylam Pharmaceuticals, Inc.	Komplementfaktor-b (cfb)-irna-zusammensetzungen und verfahren zur verwendung davon
KR20230005933A (ko)	2020-05-01	2023-01-10	아이오니스 파마수티컬즈, 인코포레이티드	Atxn1을 조정하는 화합물 및 방법
CN115551519A (zh)	2020-05-11	2022-12-30	基因泰克公司	用于治疗神经系统疾病的补体组分c1s抑制剂以及相关的组合物、系统和使用它们的方法
EP4150085A1 (de)	2020-05-11	2023-03-22	Genentech, Inc.	Komplementkomponente c1r-inhibitoren zur behandlung einer neurologischen erkrankung sowie zugehörige zusammensetzungen, systeme und verfahren zur verwendung davon
BR112022022889A2 (pt)	2020-05-11	2023-04-04	Stoke Therapeutics Inc	Oligômeros antissentido de opa1 para tratamento de condições e doenças
WO2021231204A1 (en)	2020-05-11	2021-11-18	Genentech, Inc.	Complement component 4 inhibitors for treating neurological diseases, and related compositons, systems and methods of using same
TW202208628A (zh)	2020-05-13	2022-03-01	瑞士商赫孚孟拉羅股份公司	靶向顆粒蛋白前體之寡核苷酸促效劑
WO2021231698A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl)
WO2021231692A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of otoferlin (otof)
EP4150088A1 (de)	2020-05-15	2023-03-22	Korro Bio, Inc.	Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von argininosuccinat-synthetase (ass1)
WO2021231691A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of retinoschisin 1 (rsi)
WO2021231673A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2)
EP4150077A1 (de)	2020-05-15	2023-03-22	Korro Bio, Inc.	Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von transmembrankanalähnlichem protein 1 (tmc1)
WO2021231679A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2)
WO2021231680A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2)
EP4153746A1 (de)	2020-05-21	2023-03-29	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur hemmung der marc1-genexpression
WO2021233551A1 (en)	2020-05-22	2021-11-25	F.Hoffmann-La Roche Ag	Oligonucleotides for splice modulation of card9
EP4157264A4 (de)	2020-05-27	2024-06-19	The Regents of the University of California	Zusammensetzungen und verfahren zur transdifferenzierung von zellen
US11408000B2 (en)	2020-06-03	2022-08-09	Triplet Therapeutics, Inc.	Oligonucleotides for the treatment of nucleotide repeat expansion disorders associated with MSH3 activity
US20230203496A1 (en)	2020-06-09	2023-06-29	Alnylam Pharmaceuticals, Inc.	Sirna compositions and methods for silencing gpam (glycerol-3-phosphate acyltransferase 1, mitochondrial) expression
EP4162050A1 (de)	2020-06-09	2023-04-12	Alnylam Pharmaceuticals, Inc.	Rnai-zusammensetzungen und verfahren zur verwendung davon zur verabreichung durch inhalation
US20230212572A1 (en)	2020-06-09	2023-07-06	Roche Innovation Center Copenhagen A/S	Guanosine Analogues for Use in Therapeutics Polynucleotides
AU2021292296A1 (en)	2020-06-18	2023-01-19	Alnylam Pharmaceuticals, Inc.	Xanthine dehydrogenase (XDH) iRNA compositions and methods of use thereof
AR122722A1 (es)	2020-06-24	2022-09-28	Vir Biotechnology Inc	Anticuerpos que neutralizan el virus de la hepatitis b y sus usos
JP2023531509A (ja)	2020-06-25	2023-07-24	シンソークス，インコーポレイテッド	Ｉｌ－２コンジュゲートおよび抗ｅｇｆｒ抗体を用いる免疫腫瘍学併用療法
AR122731A1 (es)	2020-06-26	2022-10-05	Hoffmann La Roche	Oligonucleótidos mejorados para modular la expresión de fubp1
IL298530A (en)	2020-06-29	2023-01-01	Ionis Pharmaceuticals Inc	Compounds and methods for modulating plp1
IL299771A (en)	2020-07-10	2023-03-01	Inst Nat Sante Rech Med	Methods and compounds for the treatment of epilepsy
WO2022011214A1 (en)	2020-07-10	2022-01-13	Alnylam Pharmaceuticals, Inc.	Circular sirnas
WO2022018155A1 (en)	2020-07-23	2022-01-27	F. Hoffmann-La Roche Ag	Lna oligonucleotides for splice modulation of stmn2
WO2022018187A1 (en)	2020-07-23	2022-01-27	F. Hoffmann-La Roche Ag	Oligonucleotides targeting rna binding protein sites
KR20230043914A (ko)	2020-07-28	2023-03-31	아이오니스 파마수티컬즈, 인코포레이티드	App 발현을 감소시키기 위한 화합물 및 방법
TW202221123A (zh)	2020-08-07	2022-06-01	美商Ionis製藥公司	調節ｓｃｎ２ａ之化合物及方法
EP4200419A2 (de)	2020-08-21	2023-06-28	F. Hoffmann-La Roche AG	Verwendung von a1cf-inhibitoren zur behandlung von hepatitis-b-virusinfektionen
WO2022056454A2 (en)	2020-09-14	2022-03-17	President And Fellows Of Harvard College	Methods and compositions for treating hpv-positive cancers
IL301306A (en)	2020-09-16	2023-05-01	Harvard College	Methods of treating an individual that has failed an anti-pd-1/anti-pd-l1 therapy
TW202227102A (zh)	2020-09-22	2022-07-16	瑞典商阿斯特捷利康公司	治療脂肪肝病之方法
EP4217489A1 (de)	2020-09-24	2023-08-02	Alnylam Pharmaceuticals, Inc.	Dipeptidylpeptidase 4 (dpp4)-irna-zusammensetzungen und verfahren zur verwendung davon
TW202229552A (zh)	2020-10-05	2022-08-01	美商艾拉倫製藥股份有限公司	Ｇ蛋白－偶合受體７５（ＧＰＲ７５）ｉＲＮＡ組成物及其使用方法
WO2022076596A1 (en)	2020-10-06	2022-04-14	Codiak Biosciences, Inc.	Extracellular vesicle-aso constructs targeting stat6
JP2023546010A (ja)	2020-10-09	2023-11-01	シンソークス，インコーポレイテッド	Ｉｌ－２コンジュゲートを用いた免疫腫瘍療法
IL301611A (en)	2020-10-09	2023-05-01	Synthorx Inc	Immuno oncology combination therapy with il-2 conjugates and pembrolizumab
AU2021365822A1 (en)	2020-10-21	2023-06-08	Alnylam Pharmaceuticals, Inc.	Methods and compositions for treating primary hyperoxaluria
CN116761885A (zh)	2020-10-23	2023-09-15	斯克利普斯研究所	包含非天然核苷酸的多核苷酸的逆转录
WO2022087329A1 (en)	2020-10-23	2022-04-28	Alnylam Pharmaceuticals, Inc.	Mucin 5b (muc5b) irna compositions and methods of use thereof
WO2022103999A1 (en)	2020-11-13	2022-05-19	Alnylam Pharmaceuticals, Inc.	COAGULATION FACTOR V (F5) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
JP7820374B2 (ja)	2020-11-18	2026-02-25	アイオーニスファーマシューティカルズ，インコーポレーテッド	アンジオテンシノーゲン発現を調節するための化合物及び方法
CA3202708A1 (en)	2020-11-23	2022-05-27	Alpha Anomeric Sas	Nucleic acid duplexes
EP4256053A1 (de)	2020-12-01	2023-10-11	Alnylam Pharmaceuticals, Inc.	Verfahren und zusammensetzungen zur hemmung der hao1 (hydroxysäureoxidase 1 (glycolatoxidase))-genexpression
WO2022117747A2 (en)	2020-12-03	2022-06-09	F. Hoffmann-La Roche Ag	Antisense oligonucleotides targeting atxn3
AR124229A1 (es)	2020-12-03	2023-03-01	Hoffmann La Roche	Oligonucleótidos antisentido que actúan sobre atxn3
JP2023553069A (ja)	2020-12-08	2023-12-20	エフ．ホフマン－ラロシュアーゲー	ホスホロジチオエートオリゴヌクレオチドの新規合成
WO2022125490A1 (en)	2020-12-08	2022-06-16	Alnylam Pharmaceuticals, Inc.	Coagulation factor x (f10) irna compositions and methods of use thereof
GB2603454A (en)	2020-12-09	2022-08-10	Ucl Business Ltd	Novel therapeutics for the treatment of neurodegenerative disorders
CR20230308A (es)	2020-12-11	2023-09-08	Civi Biopharma Inc	Entrega oral de conjugados antisentido que tienen por blanco a pcsk9
US12018261B2 (en)	2020-12-18	2024-06-25	Ionis Pharmaceuticals, Inc.	Compounds and methods for modulating factor XII
JP2023553710A (ja)	2020-12-18	2023-12-25	エフ．ホフマン－ラロシュアーゲー	プログラニュリンを標的とするためのアンチセンスオリゴヌクレオチド
CN116670282A (zh)	2020-12-22	2023-08-29	豪夫迈·罗氏有限公司	靶向xbp1的寡核苷酸
WO2022147214A2 (en)	2020-12-31	2022-07-07	Alnylam Pharmaceuticals, Inc.	Cyclic-disulfide modified phosphate based oligonucleotide prodrugs
EP4271695A2 (de)	2020-12-31	2023-11-08	Alnylam Pharmaceuticals, Inc.	Auf 2'-modifiziertem nukleosid basierende oligonukleotid-prodrugs
EP4274896A1 (de)	2021-01-05	2023-11-15	Alnylam Pharmaceuticals, Inc.	Komplementkomponente 9 (c9)-irna-zusammensetzungen und verfahren zur verwendung davon
TW202246500A (zh)	2021-02-02	2022-12-01	瑞士商赫孚孟拉羅股份公司	用於抑制ｒｔｅｌ１表現之增強型寡核苷酸
TW202302148A (zh)	2021-02-12	2023-01-16	美商欣爍克斯公司	使用ｉｌ－２接合物和抗ｐｄ－１抗體或其抗原結合片段的肺癌組合療法
EP4291654A2 (de)	2021-02-12	2023-12-20	Alnylam Pharmaceuticals, Inc.	Superoxid-dismutase-1 (sod1)-irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung oder vorbeugung von mit superoxid-dismutase 1 (sod1-) assoziierten neurodegenerativen erkrankungen
TW202245843A (zh)	2021-02-12	2022-12-01	美商欣爍克斯公司	Ｉｌ－２接合物及西米普利單抗（ｃｅｍｉｐｌｉｍａｂ）之皮膚癌組合療法
US20240167036A1 (en)	2021-02-17	2024-05-23	Lonza Sales Ag	Extracellular vesicle-nlrp3 antagonist
EP4294456A1 (de)	2021-02-17	2023-12-27	Lonza Sales AG	Extrazelluläre vesikel, die über einen optimierten linker mit einem biologisch aktiven molekül verbunden sind und eine verankerungseinheit
WO2022182864A1 (en)	2021-02-25	2022-09-01	Alnylam Pharmaceuticals, Inc.	Prion protein (prnp) irna compositions and methods and methods of use thereof
JP2024515423A (ja)	2021-02-26	2024-04-10	アルナイラムファーマシューティカルズ，インコーポレイテッド	ケトヘキソキナーゼ（ＫＨＫ）ｉＲＮＡ組成物およびその使用方法
AU2022231003A1 (en)	2021-03-04	2023-09-14	Alnylam Pharmaceuticals, Inc.	Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof
EP4305169A1 (de)	2021-03-12	2024-01-17	Alnylam Pharmaceuticals, Inc.	Glykogensynthasekinase-3-alpha (gsk3a)-irna-zusammensetzungen und verfahren zur verwendung davon
IL307239A (en)	2021-03-29	2023-11-01	Alnylam Pharmaceuticals Inc	Preparations containing Huntingtin IRNA factor (HTT) and methods of using them
US20250243244A1 (en)	2021-03-31	2025-07-31	Entrada Therapeutics, Inc.	Cyclic cell penetrating peptides
WO2022212153A1 (en)	2021-04-01	2022-10-06	Alnylam Pharmaceuticals, Inc.	Proline dehydrogenase 2 (prodh2) irna compositions and methods of use thereof
KR20230166101A (ko)	2021-04-01	2023-12-06	론자 세일즈 아게	세포외 소포 조성물
JP7688152B2 (ja)	2021-04-16	2025-06-03	ギリアードサイエンシーズ，インコーポレイテッド	アミドを使用してカルバヌクレオシドを調製する方法
BR112023022284A2 (pt)	2021-04-26	2023-12-26	Alnylam Pharmaceuticals Inc	Composições de irna de protease transmembrana, serina 6 (tmprss6) e métodos de uso da mesma
EP4330396A1 (de)	2021-04-29	2024-03-06	Alnylam Pharmaceuticals, Inc.	Signalwandler und aktivator von transkriptionsfaktor 6 (stat6)-irna-zusammensetzungen und verfahren zur verwendung davon
AU2022271873A1 (en)	2021-05-10	2024-01-04	Entrada Therapeutics, Inc.	Compositions and methods for intracellular therapeutics
EP4337261A2 (de)	2021-05-10	2024-03-20	Entrada Therapeutics, Inc.	Zusammensetzungen und verfahren zur modulation des spleissens von mrna
WO2022240721A1 (en)	2021-05-10	2022-11-17	Entrada Therapeutics, Inc.	Compositions and methods for modulating interferon regulatory factor-5 (irf-5) activity
EP4341401A1 (de)	2021-05-18	2024-03-27	Alnylam Pharmaceuticals, Inc.	Natriumglucose-cotransporter-2-(sglt2)-irna-zusammensetzungen und verfahren zur verwendung davon
EP4341405A1 (de)	2021-05-20	2024-03-27	Korro Bio, Inc.	Verfahren und zusammensetzungen für adar-vermittelte bearbeitung
WO2022256283A2 (en)	2021-06-01	2022-12-08	Korro Bio, Inc.	Methods for restoring protein function using adar
JP2024522996A (ja)	2021-06-02	2024-06-25	アルナイラムファーマシューティカルズ，インコーポレイテッド	パタチン様ホスホリパーゼドメイン含有３（ＰＮＰＬＡ３）ｉＲＮＡ組成物およびその使用方法
TW202313679A (zh)	2021-06-03	2023-04-01	美商欣爍克斯公司	包含il-2接合物及pd-1拮抗劑之頭頸癌組合療法
BR112023025224A2 (pt)	2021-06-04	2024-02-27	Alnylam Pharmaceuticals Inc	Quadro de leitura aberto 72 do cromossomo humano 9 (c9orf72) composições de agente de irna e métodos de uso dos mesmos
EP4351541A2 (de)	2021-06-08	2024-04-17	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur behandlung oder prävention von erkrankungen im zusammenhang mit morbus stargardt und/oder retinal-bindendem protein 4 (rbp4)
JP2024524874A (ja)	2021-06-08	2024-07-09	エフ．ホフマン－ラロシュアーゲー	オリゴヌクレオチドプログラニュリンアゴニスト
EP4355759A4 (de)	2021-06-18	2026-05-13	Ionis Pharmaceuticals Inc	Verbindungen und verfahren zur reduzierung der ifnar1-expression
AU2022297448A1 (en)	2021-06-22	2024-01-04	AcuraStem Incorporated	Pikfyve antisense oligonucleotides
GEAP202416440A (en)	2021-06-23	2024-04-25	Entrada Therapeutics Inc	Antisense compounds and methods for targeting cug repeats
US20230194709A9 (en)	2021-06-29	2023-06-22	Seagate Technology Llc	Range information detection using coherent pulse sets with selected waveform characteristics
US20250034564A1 (en)	2021-06-29	2025-01-30	Korro Bio, Inc.	Methods and Compositions for ADAR-Mediated Editing
MX2023015489A (es)	2021-06-30	2024-01-19	Alnylam Pharmaceuticals Inc	Metodos y composiciones para tratar un trastorno asociado al angiotensinogeno (agt).
WO2023283403A2 (en)	2021-07-09	2023-01-12	Alnylam Pharmaceuticals, Inc.	Bis-rnai compounds for cns delivery
WO2023003805A1 (en)	2021-07-19	2023-01-26	Alnylam Pharmaceuticals, Inc.	Methods and compositions for treating subjects having or at risk of developing a non-primary hyperoxaluria disease or disorder
KR20240036041A (ko)	2021-07-21	2024-03-19	알닐람 파마슈티칼스 인코포레이티드	대사 장애-연관 표적 유전자 iRNA 조성물 및 이의 사용 방법
MX2024000996A (es)	2021-07-21	2024-06-28	AcuraStem Incorporated	Oligonucleótido antisentido unc13a.
JP2024528701A (ja)	2021-07-23	2024-07-30	アルナイラムファーマシューティカルズ，インコーポレイテッド	ベータカテニン（ＣＴＮＮＢ１）ｉＲＮＡ組成物およびその使用方法
JP2024529437A (ja)	2021-07-29	2024-08-06	アルナイラムファーマシューティカルズ，インコーポレイテッド	３－ヒドロキシ－３－メチルグリタル－ＣＯＡレダクターゼ（ＨＭＧＣＲ）ｉＲＮＡ組成物およびその使用方法
TW202328445A (zh)	2021-08-03	2023-07-16	美商艾拉倫製藥股份有限公司	甲狀腺素運載蛋白（ＴＴＲ）ｉＲＮＡ組成物及其使用方法
PE20241132A1 (es)	2021-08-04	2024-05-24	Alnylam Pharmaceuticals Inc	Composiciones de arni y metodos para silenciar el angiotensinogeno (agt)
IL310407A (en)	2021-08-13	2024-03-01	Alnylam Pharmaceuticals Inc	Factor XII (F12) IRNA compositions and methods of using them
WO2023021046A1 (en)	2021-08-16	2023-02-23	Vib Vzw	Oligonucleotides for modulating synaptogyrin-3 expression
JP7719954B2 (ja)	2021-08-18	2025-08-06	ギリアードサイエンシーズ，インコーポレイテッド	リン脂質化合物並びにその製造方法及び使用方法
MX2024002440A (es)	2021-08-31	2024-03-08	Alnylam Pharmaceuticals Inc	Composiciones de acido ribonucleico de interferencia (arni) del efector b similar al factor de fragmentacion de adn subunidad alfa (dffa) que induce la muerte celular (cideb) y metodos de uso de estas.
US11833221B2 (en)	2021-09-01	2023-12-05	Ionis Pharmaceuticals, Inc.	Oligomeric compounds for reducing DMPK expression
EP4395829A1 (de)	2021-09-01	2024-07-10	Entrada Therapeutics, Inc.	Verbindungen und verfahren zum überspringen von exon 44 bei duchenne-muskeldystrophie
JP2024535850A (ja)	2021-09-17	2024-10-02	アルナイラムファーマシューティカルズ，インコーポレイテッド	補体成分（Ｃ３）をサイレンシングするためのｉＲＮＡ組成物および方法
EP4405478A1 (de)	2021-09-20	2024-07-31	Alnylam Pharmaceuticals, Inc.	Inhibinuntereinheits-beta-e (inhbe)-modulatorzusammensetzungen und verfahren zur verwendung davon
MX2024003519A (es)	2021-09-24	2024-04-01	Alnylam Pharmaceuticals Inc	Composiciones de agentes de acido ribonucleico de interferencia (arni) de proteina tau asociada a microtubulos (mapt) y sus metodos de uso.
EP4408999A1 (de)	2021-09-29	2024-08-07	F. Hoffmann-La Roche AG	Rna-editierung
JP2024537711A (ja)	2021-09-30	2024-10-16	サレプタセラピューティクス，インコーポレイテッド	１つ以上の脱塩基ユニットを有するアンチセンスオリゴヌクレオチド
CA3233755A1 (en)	2021-10-01	2023-04-06	Adarx Pharmaceuticals, Inc.	Prekallikrein-modulating compositions and methods of use thereof
IL311864A (en)	2021-10-15	2024-06-01	Alnylam Pharmaceuticals Inc	IRNA compositions for extrahepatic administration and methods of using them
AU2022370009A1 (en)	2021-10-22	2024-05-16	Korro Bio, Inc.	Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
WO2023070086A1 (en)	2021-10-22	2023-04-27	Sarepta Therapeutics, Inc.	Morpholino oligomers for treatment of peripheral myelin protein 22 related diseases
CA3234636A1 (en)	2021-10-29	2023-05-04	Alnylam Pharmaceuticals, Inc.	Complement factor b (cfb) irna compositions and methods of use thereof
TW202334418A (zh)	2021-10-29	2023-09-01	美商艾拉倫製藥股份有限公司	杭丁頓（ＨＴＴ）ｉＲＮＡ劑組成物及其使用方法
WO2023078883A1 (en)	2021-11-03	2023-05-11	F. Hoffmann-La Roche Ag	Oligonucleotides for modulating apolipoprotein e4 expression
CA3237769A1 (en)	2021-11-10	2023-05-19	University Of Rochester	Gata4-targeted therapeutics for treatment of cardiac hypertrophy
IL312635A (en)	2021-11-11	2024-07-01	Hoffmann La Roche	Pharmaceutical combinations for treatment of hbv
US20250011767A1 (en)	2021-11-18	2025-01-09	Circularis Biotechnologies, Inc.	Compositions and methods for production of circular nucleic acid molecules
WO2023092102A1 (en)	2021-11-19	2023-05-25	Sanegene Bio Usa Inc.	Double stranded rna targeting angiopoietin-like 3 (angptl-3) and methods of use thereof
EP4437106A2 (de)	2021-11-24	2024-10-02	Prime Medicine, Inc.	Verfahren und zusammensetzungen zur verhinderung der reparatur von fehlpaarungen
JP2025501682A (ja)	2021-12-03	2025-01-23	クラリスコーポレーション	改変された骨格化学を有するギャップマーアンチセンスオリゴヌクレオチド
CN118434858A (zh)	2021-12-07	2024-08-02	豪夫迈·罗氏有限公司	靶向actl6b的反义寡核苷酸
GB202117758D0 (en)	2021-12-09	2022-01-26	Ucl Business Ltd	Therapeutics for the treatment of neurodegenerative disorders
WO2023111210A1 (en)	2021-12-17	2023-06-22	F. Hoffmann-La Roche Ag	Combination of oligonucleotides for modulating rtel1 and fubp1
JP2024546887A (ja)	2021-12-17	2024-12-26	ジェネンテック，インコーポレイテッド	オリゴヌクレオチドｇｂａアゴニスト
EP4453206A1 (de)	2021-12-20	2024-10-30	F. Hoffmann-La Roche AG	Threose-nukleinsäure-antisense-oligonukleotide und verfahren dafür
WO2023122573A1 (en)	2021-12-20	2023-06-29	Synthorx, Inc.	Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
KR20240126870A (ko)	2021-12-22	2024-08-21	캠프4 테라퓨틱스 코포레이션	조절 rna들을 표적으로 하는 안티센스 올리고뉴클레오티드를 사용한 유전자 전사의 조절
WO2023122750A1 (en)	2021-12-23	2023-06-29	Synthorx, Inc.	Cancer combination therapy with il-2 conjugates and cetuximab
CN119095963A (zh)	2022-01-10	2024-12-06	杭州浩博医药有限公司	乙型肝炎病毒(hbv)表达的调节
WO2023141507A1 (en)	2022-01-20	2023-07-27	Genentech, Inc.	Antisense oligonucleotides for modulating tmem106b expression
EP4469575A2 (de)	2022-01-24	2024-12-04	Alnylam Pharmaceuticals, Inc.	Enzym-irna-wirkstoffzusammensetzungen für den heparinsulfatbiosyntheseweg und verfahren zur verwendung davon
WO2023150181A1 (en)	2022-02-01	2023-08-10	President And Fellows Of Harvard College	Methods and compositions for treating cancer
WO2023152369A1 (en)	2022-02-14	2023-08-17	INSERM (Institut National de la Santé et de la Recherche Médicale)	Nucleic acid mir-9 inhibitor for the treatment of cystic fibrosis
US20240167040A1 (en)	2022-02-21	2024-05-23	Hoffmann-La Roche Inc.	Antisense oligonucleotide
EP4514968A1 (de)	2022-04-28	2025-03-05	AcuraStem Incorporated	Syf2-antisense-oligonukleotide
WO2023220561A1 (en)	2022-05-09	2023-11-16	Sanegene Bio Usa Inc.	Double stranded rna targeting 17-beta hydroxysteroiddehydrogenase 13 (hsd17b13) and methods of use thereof
CN119173632A (zh)	2022-05-10	2024-12-20	豪夫迈·罗氏有限公司	靶向cfp-elk1基因间区域的反义寡核苷酸
JP2025516680A (ja)	2022-05-13	2025-05-30	アルナイラムファーマシューティカルズ，インコーポレイテッド	一本鎖ループオリゴヌクレオチド
KR20250011958A (ko)	2022-05-18	2025-01-22	에프. 호프만-라 로슈 아게	Rna 결합 단백질 부위를 표적으로 하는 개선된 올리고뉴클레오티드
AU2023283551A1 (en)	2022-06-10	2024-12-19	Camp4 Therapeutics Corporation	Methods of modulating progranulin expression using antisense oligonucleotides targeting regulatory rnas
CN119365600A (zh)	2022-06-17	2025-01-24	豪夫迈·罗氏有限公司	靶向颗粒蛋白前体的反义寡核苷酸
EP4547683A2 (de)	2022-06-30	2025-05-07	Alnylam Pharmaceuticals, Inc.	Oligonukleotid-prodrugs auf basis von mit cyclischem disulfid modifiziertem phosphat
WO2024017990A1 (en)	2022-07-21	2024-01-25	Institut National de la Santé et de la Recherche Médicale	Methods and compositions for treating chronic pain disorders
KR20250054842A (ko)	2022-07-29	2025-04-23	리제너론 파마슈티칼스 인코포레이티드	뇌 및 근육으로의 트랜스페린 수용체(tfr)-매개 전달을 위한 조성물 및 방법
AU2023320578A1 (en)	2022-08-05	2025-02-13	Sanegene Bio Usa Inc.	Double stranded rna targeting angiotensinogen (agt) and methods of use thereof
WO2024040041A1 (en)	2022-08-15	2024-02-22	Dicerna Pharmaceuticals, Inc.	Regulation of activity of rnai molecules
JP2025527531A (ja)	2022-08-18	2025-08-22	アルナイラムファーマシューティカルズ，インコーポレイテッド	ユニバーサル非標的ｓｉｒｎａ組成物およびその使用方法
EP4577650A1 (de)	2022-08-25	2025-07-02	Life Edit Therapeutics, Inc.	Chemische modifikation von guide-rnas mit verriegelter nukleinsäure zur rna-geführten nukleasevermittelten geneditierung
JP2025530741A (ja)	2022-08-29	2025-09-17	ユニヴァーシティオヴロチェスター	アンチセンスオリゴヌクレオチドベースの抗線維化治療剤
EP4332221A1 (de)	2022-08-29	2024-03-06	Roche Innovation Center Copenhagen A/S	Threose-nukleinsäure-antisense-oligonukleotide und verfahren dafür
IL318655A (en)	2022-09-06	2025-03-01	Hoffmann La Roche	Double RNA molecule for ocular administration
TW202424193A (zh)	2022-09-15	2024-06-16	美商艾拉倫製藥股份有限公司	第１３型１７β－羥基類固醇去氫酶（ＨＳＤ１７Ｂ１３）ｉＲＮＡ組成物及其使用方法
JP2025533454A (ja)	2022-09-21	2025-10-07	サレプタセラピューティクス，インコーポレイテッド	Ｄｍｄアンチセンスオリゴヌクレオチド介在性エクソンスキッピング効率
CN120239607A (zh)	2022-09-23	2025-07-01	Ionis制药公司	用于降低mecp2表达的化合物和方法
JP2025532985A (ja)	2022-09-30	2025-10-03	アルナイラムファーマシューティカルズ，インコーポレイテッド	修飾二本鎖ｒｎａ剤
IL320218A (en)	2022-10-14	2025-06-01	Sanegene Bio Usa Inc	Small interfering RNA targeting C3 and its uses
WO2024098061A2 (en)	2022-11-04	2024-05-10	Genkardia Inc.	Oligonucleotide-based therapeutics targeting cyclin d2 for the treatment of heart failure
CN120693347A (zh)	2022-11-04	2025-09-23	瑞泽恩制药公司	钙电压门控通道辅助亚基γ1(CACNG1)结合蛋白和CACNG1介导的向骨骼肌的递送
WO2024107765A2 (en)	2022-11-14	2024-05-23	Regeneron Pharmaceuticals, Inc.	Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
JP2025540101A (ja)	2022-12-01	2025-12-11	キャンプ４セラピューティクスコーポレイション	調節ｒｎａを標的とするアンチセンスオリゴヌクレオチドを用いたｓｙｎｇａｐ１遺伝子転写の調節
WO2024126654A1 (en)	2022-12-14	2024-06-20	F. Hoffmann-La Roche Ag	Antisense oligonucleotides targeting actl6b
CN120569477A (zh)	2022-12-19	2025-08-29	美国圣因生物股份有限公司	靶向cfb的小干扰rna及其用途
WO2024136899A1 (en)	2022-12-21	2024-06-27	Synthorx, Inc.	Cancer therapy with il-2 conjugates and chimeric antigen receptor therapies
CN120752339A (zh)	2023-01-06	2025-10-03	国家医疗保健研究所	静脉内施用用于治疗疼痛的反义寡核苷酸
WO2024155986A2 (en)	2023-01-20	2024-07-25	AcuraStem Incorporated	Unc13a antisense oligonucleotides
WO2024160756A1 (en)	2023-01-30	2024-08-08	Vib Vzw	Suppressors of tauopathies
AU2024215901A1 (en)	2023-01-31	2025-07-24	AcuraStem Incorporated	Syf2 antisense oligonucleotides
IL322380A (en)	2023-02-06	2025-09-01	AcuraStem Incorporated	PIKFYVE Antisense Oligonucleotides
AU2024217843A1 (en)	2023-02-09	2025-07-31	Alnylam Pharmaceuticals, Inc.	Reversir molecules and methods of use thereof
WO2024175586A2 (en)	2023-02-21	2024-08-29	Vib Vzw	Inhibitors of synaptogyrin-3 expression
JP2026507051A (ja)	2023-02-21	2026-02-27	ブイアイビーブイゼットダブリュ	シナプトギリン－３発現を調節するためのオリゴヌクレオチド
US20240309383A1 (en)	2023-02-24	2024-09-19	Suzhou Sanegene Bio Inc.	Small interfering rna targeting hbv and uses thereof
WO2024186673A2 (en)	2023-03-03	2024-09-12	Sanegene Bio Usa Inc.	Small interfering rna targeting apoc3 and uses thereof
TW202444349A (zh)	2023-03-20	2024-11-16	美商欣爍克斯公司	使用ｉｌ－２綴合物之癌症療法
UY40699A (es)	2023-04-05	2024-08-30	Ionis Pharmaceuticals Inc	Compuestos y métodos para reducir la expresión de pln
CN121816199A (zh)	2023-04-12	2026-04-07	阿尔尼拉姆制药公司	双链rna药剂的肝外递送
CN121285630A (zh)	2023-04-20	2026-01-06	阿达尔克斯制药有限公司	Mapt调节组合物及其使用方法
WO2024220746A2 (en)	2023-04-21	2024-10-24	Flagship Pioneering Innovations Vii, Llc	Rnai agents targeting fatty acid synthase and related methods
TW202442246A (zh)	2023-04-27	2024-11-01	美商薩羅塔治療公司	用於治療慢性腎病之反義寡聚物
CN121079412A (zh)	2023-04-28	2025-12-05	比姆医疗股份有限公司	经修饰的指导rna
WO2024227765A2 (en)	2023-05-04	2024-11-07	F. Hoffmann-La Roche Ag	Oligonucleotides capable of upregulating glucocerebrosidase expression
WO2024233864A2 (en)	2023-05-10	2024-11-14	Dicerna Pharmaceuticals, Inc.	Galnac-conjugated rnai oligonucleotides
CN121729491A (zh)	2023-05-12	2026-03-24	阿尔尼拉姆制药公司	单链环寡核苷酸
KR20260021635A (ko)	2023-05-12	2026-02-13	아다르엑스 파마슈티컬스, 인크.	Nmda 리간드 접합 화합물 및 이의 용도
IL324720A (en)	2023-05-26	2026-01-01	Adarx Pharmaceuticals Inc	SOD1 modulators and methods of using them
KR20260026070A (ko)	2023-06-16	2026-02-25	에프. 호프만-라 로슈 아게	Jak1 발현 조절을 위한 이중 가닥 올리고뉴클레오티드
CN121712891A (zh)	2023-06-20	2026-03-20	阿达尔克斯制药有限公司	Lrrk2调节组合物及其使用方法
EP4731764A2 (de)	2023-06-21	2026-04-29	Sanegene Bio USA Inc.	Doppelsträngige rna zum targeting von proproteinkonvertase-subtilisin kexin 9 (pcsk9) und verfahren zur verwendung davon
WO2025008406A1 (en)	2023-07-04	2025-01-09	Institut National de la Santé et de la Recherche Médicale	Antisense oligonucleotides and their use for the treatment of cancer
AU2024287308A1 (en)	2023-07-13	2025-12-18	Korro Bio, Inc.	Rna-editing oligonucleotides and uses thereof
KR20260044219A (ko)	2023-07-21	2026-04-01	매로우 테라퓨틱스, 인크.	조혈 세포 표적화 접합체 및 관련 방법
AU2024297923A1 (en)	2023-07-25	2026-01-22	Flagship Pioneering Innovations Vii, Llc	Cas endonucleases and related methods
US20250092426A1 (en)	2023-07-25	2025-03-20	Flagship Pioneering Innovations Vii, Llc	Cas endonucleases and related methods
IL326321A (en)	2023-08-04	2026-04-01	Alnylam Pharmaceuticals Inc	Methods and compositions for treating CTNNB1-related disorders
WO2025038750A2 (en)	2023-08-14	2025-02-20	President And Fellows Of Harvard College	Methods and compositions for treating cancer
WO2025054459A1 (en)	2023-09-08	2025-03-13	Dicerna Pharmaceuticals, Inc.	Rnai oligonucleotide conjugates
IL327100A (en)	2023-09-15	2026-05-01	Praxis Prec Medicines Inc	Alsonarsen/PRAX-22 for use in the treatment of SCN2A-related disorders
IL326940A (en)	2023-09-21	2026-05-01	Alnylam Pharmaceuticals Inc	Activin A Receptor Type 1C (ACVR1C) IRNA Compositions and Methods of Using Them
WO2025072331A1 (en)	2023-09-26	2025-04-03	Flagship Pioneering Innovations Vii, Llc	Cas nucleases and related methods
WO2025076031A2 (en)	2023-10-03	2025-04-10	Alnylam Pharmaceuticals, Inc.	Peritoneal macrophages comprising a nanoparticle encapsulating a nucleic acid molecule and methods of use thereof
WO2025080939A1 (en)	2023-10-13	2025-04-17	Ultragenyx Pharmaceutical, Inc.	Compositions and methods for treating conditions associated with cartilage oligomeric matrix protein (comp) mutations
AU2024362420A1 (en)	2023-10-18	2026-04-23	Murdoch University	Antisense oligomers for treatment of centronuclear myopathies
WO2025096809A1 (en)	2023-10-31	2025-05-08	Korro Bio, Inc.	Oligonucleotides comprising phosphoramidate internucleotide linkages
WO2025117877A2 (en)	2023-12-01	2025-06-05	Flagship Pioneering Innovations Vii, Llc	Cas nucleases and related methods
WO2025128799A1 (en)	2023-12-12	2025-06-19	Korro Bio, Inc.	Double-stranded rna-editing oligonucleotides and uses thereof
WO2025128853A2 (en)	2023-12-13	2025-06-19	Ultragenyx Pharmaceutical Inc.	Compositions and methods for treating conditions associated with ube3a overexpression
TW202535425A (zh)	2023-12-21	2025-09-16	瑞士商赫孚孟拉羅股份公司	反義寡核苷酸
WO2025158385A1 (en)	2024-01-25	2025-07-31	Genzyme Corporation	Pegylated il-2 for suppressing adaptive immune response to gene therapy
WO2025178854A2 (en)	2024-02-19	2025-08-28	Flagship Pioneering Innovations Vii, Llc	Rnai agents targeting cideb and related methods
WO2025199231A2 (en)	2024-03-20	2025-09-25	Vertex Pharmaceuticals Incorporated	Mucin-5b (muc5b) targeted sirna and antisense oligonucleotides and methods of use thereof
WO2025207517A2 (en)	2024-03-25	2025-10-02	Synthorx, Inc.	Synthetic trna synthetases and cells comprising synthetic molecules for production of polypeptides
GB202404290D0 (en)	2024-03-26	2024-05-08	Senisca Ltd	Novel oligoncleotides
WO2025217275A2 (en)	2024-04-10	2025-10-16	Flagship Pioneering Innovations Vii, Llc	Immune cell targeted compositions and related methods
WO2025228441A2 (en)	2024-04-30	2025-11-06	Sanegene Bio Usa Inc.	Small interfering rna targeting inhbe and uses thereof
WO2025237990A1 (en)	2024-05-14	2025-11-20	Institut National de la Santé et de la Recherche Médicale	Antisense oligonucleotides and their use for the treatment of pulmonary fibrosis
WO2025252669A1 (en)	2024-06-03	2025-12-11	Evotec International Gmbh	Modified oligonucleotides for reducing atxn3 expression
WO2025255388A1 (en)	2024-06-05	2025-12-11	Camp4 Therapeutics Corporation	Modulation of syngap1 gene transcription using antisense oligonucleotides targeting regulatory rnas
WO2025259743A1 (en)	2024-06-12	2025-12-18	Alnylam Pharmaceuticals, Inc.	Dual conjugate compounds for extrahepatic delivery
WO2025259747A2 (en)	2024-06-12	2025-12-18	Alnylam Pharmaceuticals, Inc.	Dystrophy myotonic protein kinase (dmpk) irna compositions and methods of use thereof
WO2026006436A1 (en)	2024-06-25	2026-01-02	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of tar dna binding protein 43 kda (tdp43)
WO2026017140A2 (en)	2024-07-18	2026-01-22	Sanegene Bio Usa Inc.	Small interfering rna targeting fxi and uses thereof
WO2026041067A2 (en)	2024-08-20	2026-02-26	Sanegene Bio Usa Inc.	Small interfering rna targeting myostatin (mstn) and uses thereof
WO2026041784A1 (en)	2024-08-23	2026-02-26	Vib Vzw	Oligonucleotides for modulating synaptogyrin-3 expression
WO2026050243A1 (en)	2024-08-26	2026-03-05	Korro Bio, Inc.	Galnac conjugated oligonucleotides for rna editing
WO2026055461A1 (en)	2024-09-05	2026-03-12	Aperture Therapeutics, Inc.	Antibody oligonucleotide conjugates comprising an antisense polynucleotide agent conjugated to a cd33 antibody and methods of use thereof
EP4711455A1 (de)	2024-09-11	2026-03-18	Aarhus Universitet	Oligonukleotid aus kleiner künstlicher rna (smartrna) zur modulation der proteinexpression
WO2026057749A1 (en)	2024-09-11	2026-03-19	Sixfold Bioscience Ltd.	Method and product
WO2026061986A1 (en)	2024-09-17	2026-03-26	Institut National de la Santé et de la Recherche Médicale	Antisense oligonucleotide (aso)-mediated down-regulation of cd33 to safely enrich for genetically modified cells
WO2026062247A1 (en)	2024-09-20	2026-03-26	Astrazeneca Ab	Liquid-phase oligonucleotide synthesis using 2-(2-nitrophenyl)propyloxycarbonyl (nppoc) as a protecting group
WO2026080323A1 (en)	2024-10-09	2026-04-16	Quralis Corporation	Treatment of neurological diseases using modulators of unc13a gene transcripts
WO2026092658A2 (en)	2024-10-31	2026-05-07	Sanegene Bio Usa Inc.	Small interfering rna targeting amyloid beta precursor protein (app) and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4837312A (en)	1985-01-25	1989-06-06	California Institute Of Technology	Chelator-functionalized nucleosides and nucleotides and methods for making same
ES2103918T3 (es)	1991-10-17	1997-10-01	Ciba Geigy Ag	Nucleosidos biciclicos, oligonucleotidos, procedimiento para su obtencion y productos intermedios.
EP0724447B1 (de)	1991-10-24	2003-05-07	Isis Pharmaceuticals, Inc.	Derivatisierte oligonukleotide mit verbessertem aufnahmevermögen
US5559101A (en) *	1994-10-24	1996-09-24	Genencor International, Inc.	L-ribofuranosyl nucleosides
AU738170B2 (en)	1996-10-16	2001-09-13	Icn Pharmaceuticals, Inc.	Monocyclic L-nucleosides, analogs and uses thereof
US6043060A (en)	1996-11-18	2000-03-28	Imanishi; Takeshi	Nucleotide analogues
JP3756313B2 (ja) *	1997-03-07	2006-03-15	武今西	新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6794499B2 (en)	1997-09-12	2004-09-21	Exiqon A/S	Oligonucleotide analogues
CA2303299C (en)	1997-09-12	2016-02-23	Exiqon A/S	Oligonucleotide analogues
US6436640B1 (en) *	1999-03-18	2002-08-20	Exiqon A/S	Use of LNA in mass spectrometry
US6525191B1 (en)	1999-05-11	2003-02-25	Kanda S. Ramasamy	Conformationally constrained L-nucleosides

2000
- 2000-05-04 NZ NZ514348A patent/NZ514348A/en not_active IP Right Cessation
- 2000-05-04 CN CN00807070A patent/CN1349541A/zh active Pending
- 2000-05-04 HK HK02107777.2A patent/HK1048322A1/zh unknown
- 2000-05-04 EP EP00925080A patent/EP1178999B1/de not_active Revoked
- 2000-05-04 WO PCT/DK2000/000225 patent/WO2000066604A2/en not_active Ceased
- 2000-05-04 DK DK00925080T patent/DK1178999T3/da active
- 2000-05-04 DE DE60033927T patent/DE60033927T2/de not_active Revoked
- 2000-05-04 JP JP2000615633A patent/JP2002543214A/ja active Pending
- 2000-05-04 ES ES00925080T patent/ES2283298T3/es not_active Expired - Lifetime
- 2000-05-04 AU AU43918/00A patent/AU776362B2/en not_active Expired
- 2000-05-04 CN CN2011100346082A patent/CN102180924A/zh active Pending
- 2000-05-04 US US09/565,699 patent/US7053207B2/en not_active Expired - Lifetime
- 2000-05-04 KR KR1020017012177A patent/KR100782896B1/ko not_active Expired - Lifetime
- 2000-05-04 PT PT00925080T patent/PT1178999E/pt unknown
- 2000-05-04 IL IL14549700A patent/IL145497A0/xx unknown
- 2000-05-04 AT AT00925080T patent/ATE356824T1/de not_active IP Right Cessation
- 2000-05-04 CA CA002372085A patent/CA2372085C/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CA2372085C (en)	2009-10-27
WO2000066604A3 (en)	2001-01-11
WO2000066604A2 (en)	2000-11-09
IL145497A0 (en)	2002-06-30
JP2002543214A (ja)	2002-12-17
CN102180924A (zh)	2011-09-14
DE60033927D1 (de)	2007-04-26
EP1178999B1 (de)	2007-03-14
AU4391800A (en)	2000-11-17
ES2283298T3 (es)	2007-11-01
PT1178999E (pt)	2007-06-26
AU776362B2 (en)	2004-09-09
CA2372085A1 (en)	2000-11-09
KR100782896B1 (ko)	2007-12-06
KR20020013515A (ko)	2002-02-20
US20030087230A1 (en)	2003-05-08
US7053207B2 (en)	2006-05-30
HK1048322A1 (zh)	2003-03-28
CN1349541A (zh)	2002-05-15
NZ514348A (en)	2004-05-28
DE60033927T2 (de)	2007-11-29
DK1178999T3 (da)	2007-08-06
EP1178999A2 (de)	2002-02-13

Legal Events

Date

Code

Title

Description

2007-09-15

UEP

Publication of translation of european patent specification

Ref document number: 1178999

Country of ref document: EP

2011-01-15

RZN

Patent revoked

Publication	Publication Date	Title
DE60033927D1 (de)	2007-04-26	L-ribo-lna analoge
WO2001038584A3 (en)	2001-10-25	Non-aggregating, non-quenching oligomers comprising nucleotide analogues; methods of synthesis and use thereof
DE60041072D1 (de)	2009-01-22	Em nachweis
DK0691980T3 (da)	1997-12-29	7-deazapurinmodifiderende oligonukleotider
DE69920477D1 (de)	2004-10-28	2'-modifizierte oligonucleotide mit rns wirkung, die konformell eingeschränkt sind
DE69806003D1 (de)	2002-07-18	Dna polymerasen, die verbesserte fähigkeiten zum einbau markierter nukleotide besitzen
ATE416183T1 (de)	2008-12-15	Oligonukleotide mit alternierenden segmenten und deren verwendungen
ATE239090T1 (de)	2003-05-15	Methode zum generieren von einzelsträngigen dna molekülen
DE69838449D1 (de)	2007-10-31	Aminooxy-modifizierte oligonukleotide
WO2005044836A3 (de)	2007-07-19	Makromolekulare nukleotidverbindungen und methoden zu deren anwendung
WO2003064625A3 (en)	2004-04-22	Oligonucleotide compositions with enhanced efficiency
DK2295441T3 (da)	2014-07-21	Bicyklonukleosidoligonukleotidanalog
AR030961A1 (es)	2003-09-03	Secuencias de nucleotidos que intervienen en la fertilidad masculina en plantas y metodo de uso de las mismas
CA2506797A1 (en)	2004-06-10	Detectable labeled nucleoside analogs and methods of use thereof
ID24781A (id)	2000-08-10	Proses untuk memproduksi nukleotida purin
DE69815370D1 (de)	2003-07-10	Fluoreszend-konjugaten von nukleosiden und von nukleotiden, ihrer verfahren zur herstellung und ihrer verwendungen
AU2001259131A1 (en)	2001-11-07	Detection of nucleotide sequence variations via the proofreading activity of polymerases
EP1466013A4 (de)	2006-09-06	Nukleinsäurepolymerasen aus thermus scotoductus
AU2003247592A8 (en)	2004-01-19	Selective cloning of homoduplex nucleic acids
MXPA05008817A (es)	2005-10-18	Derivados de esteres lipidos de nucleotidos.
WO2001023618A3 (en)	2002-04-18	Compositions and methods for reducing oligonucleotide hybridization and priming specificity
PT1058739E (pt)	2006-08-31	Metodo para produzir perfis de expressao genica
EP1551972A4 (de)	2005-08-31	Nukleinsäuren, polypeptide, einzelnukleotid-polymorphismen sowie verfahren zur verwendung davon
EP1577318A4 (de)	2008-07-02	Nukleotidderivate und dna-mikroarray
ATE311477T1 (de)	2005-12-15	Hohe dichte markierung von dns mit modifizierte oder chromophore tragende nukleotide und benutzte dns polymerasen